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ABSTRACT
AIM: To study the profileof nutritional anemia in children and to determine the
treatment outcome of iron deficiency anemia
METHODS: A total of 150 children with confirmed anemia were enrolled in this
study. After a targeted history and clinical examination, hematological
investigations were done. Children with microcytic hypochromic anemia were
treated with oral iron and followed up after 1 and 3 months for improvement.
RESULTS: In the study population, 55 children were found to have microcytic
hypochromic, 15 children had normocytic hypochromic and 80 children had
normocytic normochromic anemia. Among the microcytic hypochromic group, the
mean hemoglobin was found to be 8.22 ± 1.27 g/dL. Symptom analysis revealed
54.5% of children with iron deficiency anemia had lethargy and 34% had
irritability. Pica was seen in 47.3% of children with microcytic hypochromic
anemia. Hemoglobin levels correlated well with red cell indices, but it was found
that 52.7% of children had normal serum ferritin levels. After treatment, it was
found that the mean hemoglobin increased from 8.25 ± 1.30g/dLto 9.17 ±
1.36g/dLafter one month and after three months, there was a further increase z
10.39 ± 1.36g/dL.
CONCLUSION: In children with iron deficiency anemia, normal or high ferritin
level should not distract the physician away from the diagnosis as co-existing
infection and inflammation may confound the picture. In cases of normocytic,
normochromic anemia, S. ferritin levels can mask a latent iron deficiency.Hence, a
therapeutic trial of oral iron is more cost effective.
KEYWORDS:    Children, Iron deficiency anemia, Red cell indices, Iron profile,
Treatment outcome.
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INTRODUCTION
1.1. History of iron deficiency:
Iron deficiency, described in various texts since ancient times, is
‘probably the most frequent nutritional deficiency in the world’. Globally
about 1.62 billion individuals are said to be suffering from iron deficiency
anemia.1 Around 1500 B.C, Papyrus Ebers, which is considered to be the
oldest manual of therapeutics, has described a similar disease condition
characterized by pallor, dyspnea, and edema.2
In 1713, Lemery and Geoffroy, and in 1747, Menghini found
residual particles which were attracted to lodestone after burning blood to
ash and thus presumed those particle to be made up of iron. The German
biochemist Felix Hoppe-Seyler (1825–1895), using absorption
spectrometry showed that hemoglobin is made up of a complex of
haematin and protein. Stokes (1819–1903), a professor of mathematics at
the University of Cambridge, showed that hemoglobin exists as two
forms and demonstrated the changes between them in response to oxygen
administration.
Bunge (1902, Basle) was the first to suggest the fact that iron
deficiency caused hypochromic anemia. He also showed that iron was
found in higher concentrations in the liver and kidneys of newborn
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infants than older infants, children or adults.  He also stated that iron
content in human milk was very low and the  iron derived from
hemoglobin in meat was poorly absorbed. This fact was very much in
contrast to today’s evidence which suggests that haem iron is rapidly
absorbed from the gastrointestinal tract. He was the first to recognize that
a high concentration of iron was present in egg yolk, spinach, apples,
lentils and beef. Koilonychia, a specific feature of iron deficiency also
represented in the ancient literature as ‘Lydney hand’ was described in
the twentieth-century by Kaznelson (1931).
In the middle of the 16th century, European physicians had treated
a disease condition known as chlorosis or "green sickness". This
condition had been treated with iron salts and other remedies (including,
oddly enough, phlebotomy) in France, by the middle of the 17th century.
Not long thereafter, Sydenham had also recommended iron as a specific
remedy for chlorosis.3
In 1832, pills containing 1.39 g of ferrous sulphate and 0.1 g of
potassium carbonate were widely recommended for chlorosis and other
conditions. These pills were introduced by Blaud. The original pills
contained 64 mg of iron. Later on, arsenic was often included to these
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pills as many physicians thought iron combined with arsenic was more
effective. This trend continued even into the 1930s.
Finally, the study of blood cell morphology was made possible by
the pioneering work of Paul Ehrlich (1854–1915) who developed aniline
dyes to stain blood films and lead to the birth of modern hematology.
Only after the 1932 studies by Heath, Strauss, and Castle that it was
shown that the response of anemia to iron was stoichometrically related
to  the  amount  of  iron  given  and  that  chlorosis  was,  indeed,  iron
deficiency.
1.2. Prevalence:
Iron deficiency is the most widespread nutritional disorder in the
world. Anemia is the most common problem among micronutrients
deficiency. Anemia affects health, education, economy and thereby,
productivity of the entire nation. Thus, anemia constitutes a public health
epidemic. The numbers are staggering. Over 30% of the world's
population is anemic, mainly due to iron deficiency. This figure is
frequently exacerbated by malaria and worm infections in developing
countries.
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Impact of anemia in South East Asia:
South East Asia has the largest number of anemic persons,
including children contributing to 12,500,000 Disability Adjusted Life-
Years (DALYs) and 324,000 deaths in this region, which is the highest in
the  world.  More  than  66%  of  the  children  in  this  region  are  anemic.  In
children aged less than two years, the prevalence of anemia may exceed
90%.4
Magnitude of Anemia in Indian Children:
Fig.1 Comparison of anemia among 6 – 35 months children–NFHS 2
and NFHS 3
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Anemia has been a big public health problem in India. The
prevalence of anemia among children less than five years of age has been
shown to be around 70% as per the data collected by National Family
Health Survey (NFHS) III, with Bihar topping the list. The prevalence of
anemia increases to 79% among children aged less than three years, with
the highest prevalence among six to twenty-three months age group. This
value, when compared to NFHS II survey done six years prior to the
NFHS  III  survey,  was  five  percent  more.  However,  the  prevalence  of
severe anemia had slightly reduced in the same period.5
Iron deficiency affects the activity of numerous enzymes adversely.
Infants, whose organs are still developing, including the brain, are
affected significantly by anemia resulting in growth retardation and
impairment of intellectual development. In these modern times where we
strive for millennium development Goal 4, this silent morbidity is
completely unacceptable as children are denied of their right to full
mental and emotional development, even before they reach a classroom.
At the same time, iron deficiency anemia can usually be prevented
easily at a very low cost. The cost-benefit ratio of implementing
preventive programs for iron deficiency is recognized as one of the
highest in the realm of public health.
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1.3. Nutritional anemia in children:
The term ‘nutritional anemia’ includes all pathological conditions
characterized by low blood hemoglobin concentration, which may be due
to a deficiency in one or several nutrients. Iron, folic acid and vitamin B12
are the main nutrients required for the synthesis of hemoglobin. By far,
the first cause of nutritional anemia worldwide is iron deficiency. Folic
acid deficiency is less common. Rarer among the main nutrient
deficiencies is Vitamin B12 deficiency. Also folic acid deficiency is often
observed with iron deficiency.4
1.4. Iron deficiency:
Iron deficiency is defined as a condition characterized by signs of
compromise in supply of iron to tissues including the erythrocyte, as there
are no mobilizable iron stores. Iron deficiency is usually the result of
inadequate bioavailable dietary iron, increased iron requirement during
rapid growth, and increased blood loss for any reason.6
Iron deficiency anemia:
Anemia, when caused by severe iron deficiency is termed as iron
deficiency anemia (IDA) and represents a very late stage of iron
deficiency. Iron deficiency anemia is commonly associated with
18
decreased physical capacity, reduced immunity and cognitive
impairment. Severe iron deficiency anemia also affects the capacity to
maintain body temperature and is also life-threatening.
Diag. 1 Stages of depletion and status of compartments of iron3
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Hemoglobin levels:
World Health Organization defined criteria, using hemoglobin
levels for anemia classification7
Hemoglobin ( g/dL)
Age Groups No anemia Mild moderate severe
6 -59 months of
age
? 11 10 – 10.9 7 – 9.9 < 7
5 – 11 years of age ? 11.5 11 – 11.4 8 – 10.9 < 8
12-14 years of age ? 12 11 – 11.9 8 – 10.9 < 8
Table - 1 : Hemoglobin values
20
Causes of iron deficiency anemia:
Decreased intake or
absorption
1. Insufficient dietary iron
2. Too early introduction or delayed
introduction of complementary feeding
without supplementation of iron
3. Poor bioavailability due to increased
absorption inhibitors and decreased
absorption enhancers
Increased requirement Rapid growth phase in infancy and early
childhood
Increased blood  loss 1. Infections (hookworm,trichuris trichura,
plasmodium, helicobacter pylori)
2. Gastrointestinal  blood loss (Meckels
diverticulum, peptic ulcer, esophageal
varices, hemorrhoids, hereditary
telangiectasia, ulcerative colitis,
diverticulosis, angiodysplasia)
3. Other causes (Hemoglobinuria,
Widespread bleeding disorders)
4. Malabsorption  (Gluten-induced
enteropathy, gastrectomy, atrophic
gastritis, chronic inflammation )
5. Bovine milk allergy
Table 2 Causes of iron deficiency anemia8
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Pathophysiology of anemia in children:
At birth, hemoglobin concentrations are normally higher than at
any other time of life. This occurs as a result of the adaptation of the fetus
to the hypoxic environment of the uterus. The neonatal reserves of
storage iron are also relatively generous.
From two months of age, the hemoglobin concentration starts
declining from a mean of 17.0 g/dL at birth and reaches a low level of
11.0 g/dL. This occurs due to breakdown of hemoglobin in order to meet
the iron needs. This decrease in hemoglobin concentration is known as
‘early anemia of infancy’. This condition is usually unresponsive to iron
treatment and hence, distinguished from the ‘late anemia of infancy’.
Thus, in a term infant, the total body iron between birth and four months
of age is almost not changed and there is only a modest need for
exogenous iron during this period.
After about four months of age, the period of continued rapid
growth begins and a gradual shift to marginal iron reserves occurs.
Between four and twelve months, blood volume is rapidly expanding and
a large amount of iron is needed in order to maintain a near constant
mean hemoglobin concentration of 12.5 g/dL. The children are highly
vulnerable to iron deficiency during this period.
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By four to six months of age, dietary iron absorption becomes
important as iron stores are usually depleted. Low birth weight babies
have less iron stores and hence, they need extra iron as well as iron at an
early age from the diet source.
During the first 15 years of life, an average of 0.8 mg of iron needs
to be absorbed each day. In addition, a small amount is also needed to
balance normal losses of iron caused by shedding of cells. Therefore,
approximately 1 mg of iron is needed daily in order to maintain positive
iron balance in childhood. This can be achieved by ensuring a dietary
intake of 8-10 mg of iron daily, since only 10% of dietary iron usually is
absorbed.
When growth is most rapid, approximately 1 mg/L of iron in
bovine and breast milk makes it difficult to maintain the body iron.
Breast-fed infants have an advantage because they absorb iron 2-3 times
more efficiently than infants fed with bovine milk.
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Dietary iron absorption:
Haem iron absorption
? Iron status
? Haem iron in the diet
? Fish, meat, poultry.
? Constitutes  less  than  10%  of  the  total
intake in developing countries.
? However, bioavailability is high.
? Calcium content in meal  (e.g. milk,
cheese)
? Method of food preparation
(temperature, time)
Non-haem iron
absorption
o Iron status
o Dietary non haem iron
? Cereals , pulses, vegetables, tubers
? Bioavailability is low
o Contamination iron
? Soil, dust, water, iron pots
Table 3 Dietary iron absorption
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Enhancers and inhibitors of iron absorption:
Enhancing
factors
Ascorbic acid  present in fruits, fruit juices,
vegetables
Fish, meat, chicken
Inhibiting factors
Phytates and other inositol phosphates
- rice (unpolished ), oats
- breakfast cereals,
- bread
Calcium (e.g. milk, cheese)
Iron binding phenolic compounds
- tea, coffee, cocoa, certain spices,
- certain vegetables
- most red wines
Nuts, peas, soybeans
Table 4 Enhancing and inhibiting factors9
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Diag. 2 Adverse effects of anemia
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Sequence of events in iron deficiency anemia
Depletion of iron stores:
This is the first event which occurs in a state of negative iron
balance. Iron stores are depleted in order to enhance hemoglobin
production. As a result, iron absorption is increased even when serum
iron level is still normal and even before anemia develops. During this
stage, the serum ferritin would have already fallen.
Iron-deficient erythropoiesis:
When the serum ferritin drops below 15ng/L, the serum transferrin
saturation starts to fall to less than 15%. This occurs due to a fall in serum
iron and a rise in transferrin concentration. At this stage, iron-deficient
erythropoiesis occurs characterized by increasing concentrations of red
cell protoporphyrin and serum transferrin receptors. But, the hemoglobin,
mean corpuscular volume (MCV) and mean corpuscular hemoglobin
(MCH) may still remain within the reference range, although the values
may rise significantly after iron therapy is given.
Iron deficiency anemia:
Frank iron deficiency anemia develops when the negative balance
continues.  The red cells at this stage become obviously microcytic,
hypochromic and poikilocytosis becomes more marked. The MCV and
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MCH are also reduced. Target cells may be present in the peripheral
smear. The reticulocyte count is also low for the degree of anemia. The
serum iron falls and serum TIBC rises. As a result, the percentage
saturation of the TIBC is usually less than 10%. This may be
accompanied frequently by increase in platelet numbers.
Iron metabolism:
Iron is present in most living organisms and is critical for normal
functioning by being part of electron transport in cytochromes and
cytochrome oxygenase. Krebs cycle, in which heme containing iron acts
as a coenzyme, is the active site of electron transport. Heme is also the
site of oxygen uptake by myoglobin and hemoglobin. Circulating red
cells in the human body has the highest concentration of iron, containing
about 1 mg of iron per ml of packed cells. The storage form of iron is
either ferritin or hemosiderin.3
At the same time, antioxidant mechanisms are needed by the body
to protect against the damage by free iron in chemical reactions that
generate free radicals such as singlet O2 or OH.
In a person with normal iron status, approximately 1 mg to 2 mg of
iron (10% of the iron in a normal diet) is absorbed each day from the
duodenal lumen into the intestinal mucosal cell (enterocyte), usually in
the ferrous (Fe2+)  state.  After  iron  is  absorbed  from  the  diet,  it  is  either
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transported by ferroportin into plasma or retained in the enterocytes as
ferritin and shed later.
The main regulating mechanism of iron content in the body is iron
absorption. The transport of iron from enterocyte to the plasma is tightly
regulated by a peptide known as hepcidin. Hepcidin is produced in the
liver and up regulated in states of inflammation. It is this process of
intestinal iron absorption that serves as the primary mechanism of iron
homeostasis.
When iron deficiency is present, hepcidin is decreased, thus
fostering enhanced absorption of iron. In contrast, during states of iron
excess or inflammation, hepcidin levels are usually increased, thereby
blocking ferroportin and limiting its ability to mobilize iron into the
plasma from enterocytes and storage sites.
Iron circulates in the plasma bound to transferrin, the iron transport
protein until it interacts with specific transferrin receptors present on the
surface of marrow erythroid cells. The iron-transferrin complex is
internalized after the interaction via clathrin-coated pits. Once
internalized, the complex is then transported to an acidic endosome,
where low pH causes the iron to be released and made available for heme
synthesis.
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Diag.3 Iron absorption in the intestine
1. Iron is absorbed in the ferrous sate from the duodenal lumen into
the enterocyte via divalent metal transporter 1 (DMT 1)
2. Iron is retained as ferritin and subsequently sloughed
3. Iron is transported across the basolateral membrane into the plasma
via ferroportin
4. Iron is bound to transferrin and transported to marrow iron stores
5. During states of iron excess or inflammation, hepcidin increase and
block ferroportin limiting the ability to mobilize iron into plasma
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Iron is then incorporated into hemoglobin within the erythroid cell
and subsequently enters the circulation. This form of iron will not become
available for reutilization until the red cell dies. At the same time, excess
iron is bound to a storage protein, apoferritin and forms ferritin.
Hemosiderin is a protein aggregate formed within in the RE system when
excess ferritin accumulates. Iron present in the hemosiderin is less readily
available.
An average red cell life span is 120 days in a normal individual,
which means about 0.8 to 1% red cells  turnover each day.  Once the red
cell reaches the end of its life span, it undergoes phagocytosis after being
recognized as senescent by reticulo-endothelial cells. Once the
hemoglobin from the ingested red cell is broken down, the iron is shuttled
back to the surface of the RE cell and presented to circulating transferrin.
1.5. Megaloblastic anemia:
Megaloblastic anemia is the most common manifestation of
deficiency of vitamin B12 and folic acid. Vitamin B12 and folic acid
deficiency primarily results in decreased capacity of DNA synthesis and
manifests  as  reduction  in  number  as  well  as  enlargement  of  all  rapidly
proliferating cells of the body, including marrow cells. The commonest
age is 3 to 8 months with maximum number of cases in 9 to 12 months.10
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Animal products such as eggs, meat, milk and other dairy products
are the main source of cobalamins. Intrinsic factor, a protein present in
the gastric juice, is required for absorption. Once bound to intrinsic
factor, the cobalamins are subsequently absorbed in the ileum and are
taken up from circulation and stored in the liver. They are then released
into circulation as and when needed. Vitamin B12 acts as a coenzyme in
two important metabolic functions which are vital to DNA synthesis and
normal cell growth. The two vital chemical reactions are concerned with
methionine synthesis and formation of succinyl CoA from methylmalonyl
CoA.
The most common cause of vitamin B12 deficiency is defective
secretion of intrinsic factor which results in inadequate vitamin B12
absorption. This condition is known as pernicious anemia and is most
common among people aged over 50 years. Other causes are
malabsorption due to surgical resections, gastrectomy and bacterial or
inflammatory diseases affecting the small intestine. There has been no
known incidence of clinical problems caused by elevation in vitamin B12
levels.
Folic acid is present in foods such as dark leafy vegetables, milk,
egg, yeast, beans and citrus fruits. It is also absorbed in the small intestine
and stored in the liver. Folate deficiency can be caused by decreased
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dietary intake, malabsorption or excessive utilization as in pregnancy,
liver-damaging diseases. Folate deficiency is characterized by
megaloblastic anemia and ultimately, severe neurological problems14.
Some peculiar features to Megaloblastic anemia include
hyperpigmentation of knuckles, terminal phalanges and mild enlargement
of liver and spleen. Other less common manifestations include
neurodevelopmental effects and abnormal movements.
1.6. Clinical features:
Iron deficiency anemia is asymptomatic in most cases. Pallor is the
most common manifestation and is identified in children over palmar
creases, palms, nail beds or conjunctivae. Pallor is associated with fall in
hemoglobin levels to 7 to 8 g/dL. When the hemoglobin decreases
further, child displays mild irritability.8
When hemoglobin decreases further to 5 g/dL, the children
complain of headache, fatigue, dizziness, shortness of breath, palpitation,
chest pain and manifest irritability, lethargy and anorexia. Hemic
murmurs may be heard on auscultation. This stage is associated with
significant physical, psychological and social consequences. Tachycardia
and high output cardiac failure occurs, when hemoglobin continues to
fall. .
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Other features include pica, pagophagia (the desire to eat ice cubes)
and plumbism, poor school performance, leg cramps, reduced resistance
to infections. Children who are iron deficient suffer from growth
impairment and tend to be shorter than non-iron deficient children. In
early iron deficiency, even before iron deficiency anemia develops, the
most important non hematological side effect is intellectual impairment,
cognitive function and motor function.11These changes are not reversible
with iron therapy and hence prevention is better than cure. Physical
examination may reveal pallor, spoon shaped nails (koilonychia),
leuconychia, platynychia, splenomegaly in severe and persistent untreated
anemia.
1.7. Investigations
Investigations for iron deficiency anemia includes complete blood
count, iron profile, peripheral smear and stool for occult blood and serum
B12 and folic acid to look for other nutritional anemias.
Complete blood count:
Most clinical laboratories now employ automated machines to
perform complete blood count to estimate hemoglobin, hematocrit
(packed cell volume), and red blood cell count. MCV, MCH and MCHC
are calculated values from hemoglobin, hematocrit, and red blood cell
count.
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Red cell indices are used in the morphologic classification of
anemias based on the size of the red blood cell as being normocytic
(normal MCV), macrocytic (increased MCV), or microcytic (decreased
MCV). . Red cell indices were first introduced by Wintrobe in 1929.
MCV =   Volume of packed cells / 1000 mL of blood        fL or ?m3
 Red blood cell count (millions / mL)
MCH =    Hemoglobin in g / 1000 mL of blood            pg/cell
                                   RBC count (millions /mL )
     MCHC =   Hemoglobin in g / 100 mL of blood   X 100     g/dL or %
  Volume of packed cells /100 mL of blood
MCV  defines  the  size  of  the  red  blood  cells  and  is  expressed  as
femtoliters (10?15; fL) or as cubic microns (?m3). MCH quantifies the
amount of hemoglobin per red blood cell. MCHC indicates the amount of
hemoglobin per unit volume. In contrast to MCH, MCHC correlates the
hemoglobin content with the volume of the cell. It is expressed as g/dl of
red blood cells or as a percentage value.
Microcytic anemias were also often described as being
hypochromic based on peripheral smear examination and MCHC when
this value was determined manually.
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Red cell distribution width (RDW), otherwise known as red cell
morphology index represents the coefficient of variation in the volume
distribution (size) of the red blood cell and is expressed as a percentage,
thereby quantifies the variation in the size of red cells (anisocytosis).
Spurious results associated with Automated Cell Counters.
? In the case of red cell agglutination, larger clumps are not counted
as red blood cells at all and doublet erythrocytes are counted as
one. This leads to a "decrease" in red cell count and a falsely
elevated MCV. Pre-warming the sample eliminates these spurious
values.
? In  hyperglycemic  conditions,  red  cells  are  swollen  as  they  are
transiently hypertonic in relation to the isotonic diluting fluid
resulting in elevated MCV. Providing some time to allow for
equilibration after dilution can avoid this spurious result.
? Conditions such as hyperlipidemia, hyperbilirubinemia, a very high
white blood cell count and high serum protein can interfere with
absorption characteristics of hemoglobin. Since hemoglobin is
quantified based on its absorption characteristics, this can result in
falsely elevated hemoglobin values.
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? Since MCH and MCHC are calculated and are not directly
measured, these indices also become abnormal when the values of
hemoglobin, red cell count, and MCV are affected.
The reference values of red cell indices and iron profile are given
in Table 2 shown below:8
Parameters Reference range
RBC count
    6m to 2 years:      3.7 to 5.3 million/cu.mm
    2 to 6 years:         4.9 to  5.3 million/cu.mm
    6 to 12 years:       4 to 5.2 million/cu.mm
PCV
1 to 23 months: 32 -42 %
2 to 9 years     : 33 -43%
10 to 17 years  : 36 -45%
MCV
1 to 23 months: 72 to  88 fL
2 to 9 years     : 76 to 90 fL
10 to 17 years  : 78 to  95 fL
MCH
1 to 23 months: 24 – 30 pg
2 to 9 years     : 25 – 31 pg
10 to 17 years  : 26 – 32 pg
MCHC 32.0 – 36.0 %
RDW 10.0 – 15.0 %
Platelet count 154000 – 400000 cells/cu.mm
Reticulocyte count <1%
37
Serum Iron 50.00 – 120.00 µg/dL
TIBC 250.00 – 400 µmol/L
Transferrin
saturation 15 - 55%
Serum Transferrin 208 – 400 mg/dL
Serum Ferritin 6.0 – 67.0 µg/L
Serum B12 140.00 – 700.00 pg/mL
Serum Folic acid 1.8-9.0 ng/mL
ESR 5-15 mm/Hr
CRP 0.01-2.80mg/L
Table 5 Red cell indices and iron profile
Erythrocyte sedimentation rate
The  rate at which red blood cells sediment in a period of one hour
is called erythrocyte sedimentation rate. ESR is a non-specific indicator
of inflammation. The high proportion of fibrinogen present during an
inflammatory process results in red blood cells sticking to each other.
This results in rouleaux formation and red blood cells settle faster.
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Peripheral smear examination:
A blood smear is used to categorize the type of anemia based on
the size, shape and color of RBC (indicators of hemoglobin content). It
also helps in identifying conditions that affect one or more type of blood
cells. Examples include anemia, myeloproliferative disorders, leukemia,
and parasitic infections. If the result from an automated cell count or a
differential count indicates the presence of abnormal WBC, RBC and/or
platelets, it has to be verified and confirmed by a good peripheral smear
examination, making it the most important investigation of hematology.
The reticulocyte count is calculated manually and it is corrected for
appropriate hemoglobin levels.
Diagnostic methods for investigating iron metabolism12
Serum iron and iron binding capacity:
The serum iron level indicates the amount of circulating iron bound
to  transferrin.  The  iron  supply  to  the  tissues  is  measured  by  serum  iron
and the saturation of the total iron-binding capacity of transferrin (TIBC).
The serum iron shows a diurnal rhythm in normal subjects, the values
being lower in the morning than in the evening. The TIBC is an indirect
measure of the circulating transferrin. Serum transferrin is determined by
adding Serum iron with TIBC. Transferrin saturation levels below 20%
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are associated iron deficiency states. Transferrin saturation is obtained by
the following formula:
   Serum iron x 100
                                         Serum transferrin
Serum Ferritin:
Serum ferritin is a non-invasive measure of iron stores and the
most convenient laboratory test to estimate iron stores as the levels
correlate with total body iron stores. In neonates, over the first 2 months
of life, the fetal hemoglobin is broken down and cord blood concentration
(median approximately 100µg/L) rises further. Thereafter, throughout
childhood and adolescence, serum ferritin levels fall to low levels
(median 20–30 µg/L). Until the onset of puberty, there is no gender
difference in ferritin values. Once puberty is attained, serum ferritin
levels rise in males. The normal serum ferritin value varies according to
the age and gender of the individual. In children less than 5 years, serum
ferritin levels less than 12 µg/L and in children more than 5 years, levels
less than 15µg/L is considered as depleted iron stores.13
Serum ferritin values falls to <15 µg/L as iron stores are depleted.
Serum ferritin values below 15µg/L are virtually specific for storage iron
depletion. However, normal values do not exclude storage iron depletion
and values above 300µg/L do not necessarily indicate iron overload.
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Confounding factors influencing Serum ferritin:
Serum ferritin is an acute-phase reactant and is increased in
conditions like infection, inflammation or malignancy. Serum ferritin is
released from the tissues when iron-rich organs are damaged as in hepatic
necrosis, chronic liver disease and bone marrow or splenic infarction in
sickle cell disease.
Serum transferrin receptors:
Serum transferrin receptor concentration reflects both iron supply
to the bone marrow and the number of erythroid precursors. It is an
important and invaluable indicator of iron deficiency in anemia of chronic
disease.
Serum folic acid levels:
Folate status is assessed by measuring folate levels in both serum
and red blood cells. Red blood cell (RBC) folate is the best indicator of
long term folate stores whereas serum folate level is an indicator of recent
folate intake. Prolonged folate deficiency is indicated by low RBC folate
values. Folate uptake into red blood cells is also affected vitamin B12
deficiency, leading to low RBC folate values even after adequate folate
intake.14
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Serum vitamin B12 levels:
A  deficiency  of  either  vitamin  B12  or  folic  acid  disrupts  the
synthesis of methionine as both are linked to the reaction pathway.  This
leads to the same symptoms and medical problems. Therefore, in a
clinical workup, measurement of both vitamins is often necessary and
treatment varies depending on which vitamin is deficient.
C-reactive protein:
C-reactive protein is an acute phase reactant and is increased in
processes such as infections, inflammatory diseases and malignant
neoplasms. Clinical symptoms, including fever, are frequently preceded
by the CRP response. Normal CRP values in healthy individuals have a
range up to 5 mg/an L. Serum CRP value rise rapidly and extensively
after onset of an acute phase response and are detectable within 6 to 8
hours and reaches the peak within 24 to 48 hours. CRP activates the
classical complement pathway. CRP is an ideal tool for clinical
monitoring as it has a half-life of only a few hours. Whenever high serum
CRP concentration persists in a clinical condition, it generally indicates
the presence of an uncontrolled infection.
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1.8. Treatment of iron deficiency anemia
The objectives of therapy in IDA are
i) To restore the hemoglobin to normal
ii) Replenish the depleted iron stores
iii) Treat etiological factors and prevent their recurrence.
Severe iron deficiency anemia can be rapidly treated with the help
of iron supplements in all sex and age groups. Whether iron
supplementation can be given daily or twice or once per week without
compromising the efficacy of supplementation is an ongoing debate and
numerous studies have been conducted. However, daily supplementation
for young children remains the current recommendation.
Oral  iron supplements should be started as soon as a diagnosis  of
IDA  is  established.  The  standard  dose  is  3  mg/kg  of  elemental  iron  per
day up to a maximum of 180 mg/day. Higher doses (6mg/kg body
weight) were previously used; but were associated with more frequent
gastrointestinal side effects. Single daily doses are effective, but 2-3
divided doses are better tolerated by children. Ideally, oral iron should be
given at least half an hour before a meal to ensure maximal absorption. It
can also be given 1-2 hours after meals.1,15,16,17
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Oral iron therapy must continue for a period of at least three
months to replenish depleted iron stores, if an adequate response to
therapy is seen. Stoppage of iron, once anemia is corrected, is the most
frequent cause for recurrence of IDA.
In  12  to  24  hours  of  starting  therapy,  there  is  replacement  of
intracellular iron enzymes leading to dramatic improvement in sense of
wellbeing, decreased irritability and increased appetite. In 36 to 48 hours,
the bone marrow responds by way of erythroid hyperplasia.  An increase
in reticulocyte count is observed in 48-72 hours and peaks in 5-7 days.
The  hemoglobin  level  rises  at  an  average  rate  of  0.15  g/dL  per  day,
usually commencing about one week after the institution of therapy.
Repletion of iron stores occurs by 1 to 3 months.
Choice of iron preparations:
Various salts have been used. Ferrous sulphate is used most
frequently, is least expensive and causes few side effects, if administered
in appropriate doses.  Ferrous sulphate tablets are available as pediatric
iron tablets of 66 mg with an elemental iron content of 20 mg. Ferric
hydroxide polymaltose complex was recently introduced salt in the
market and has fewer gastrointestinal side effects. The non-ionic iron
polymaltose, has been shown to have no oxidative potency on
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lipoproteins in healthy subjects. Hence, a better compliance is expected
than with ferrous sulphate. But, the data on efficacy are lacking.18,19
Activated hydroxyl radicals are released when ferrous compounds
are oxidized in the lumen of the gut or within the gut mucosa. These
molecules attack the gut wall resulting in a range of gastrointestinal
symptoms and discomfort. In an attempt to avoid these problems, enteric
coated ferrous formulations designed to minimize iron release in the
stomach are available. But, this may compromise the absorption of iron.
Therefore, enteric-coated tablets should not be used as maximum
absorption of iron occurs in the duodenum and proximal jejunum.
Nausea, vomiting, abdominal discomfort, diarrhea and constipation
occur in some patients. These side effects are dose related and can be
minimized by adhering to standard doses, gradual hiking up of dose and
administration of iron with or after meals.
45
Oral iron preparations:
Iron preparation Percentage of elemental iron
Ferrous sulfate 20
Exsiccated ferrous sulfate 30
Ferrous fumarate 33
Ferrous succinate 23
Ferric ammonium citrate 18
Table 6 oral iron preparations20
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Commercial iron preparation:
Iron preparation
Elemental iron
(per tab/cap or per 5 ml)
Fersolate Tab 66 mg
Tonoferon pediatric syrup
80 mg
Vitcofol syrup, Hemsi syrup,
Fesovit syrup 33 mg
Mumfer, Trifer 50 mg
Table 7 commercial oral iron preparations
Helminthic control:
Albendazole is given as a single dose (400 mg) in children more
than 2 years and as a single dose of 200 mg in children less than 2 years.
Other drugs used are single dose of Mebendazole (500 mg), single dose
of Levamisole (2.5 mg/kg) or single dose of Pyrantel (10 mg/kg).
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1.9. Prevention
Diag.4. Methods of prevention and correction of iron deficiency and
IDA
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Food-based Interventions:
Dietary diversification1
Improvement of nutritional status can be achieved by educating
households on methods of food preparation, including minimizing the
amount of inhibitors of iron absorption in the diet and recommending
minimal cooking in small amount of water of vegetables rich in vitamin
C, folate and other water soluble vitamins. Also, the bioavailability of
iron is improved by adding a small portion of haem iron containing diets
like meat or fish, since iron content is low in cereals and tuber based
diets.
Food fortification
Food fortification is being done in many countries as a part of
prevention of anemia. The best method is to fortify a staple food of the
local population, since it will be consumed in significant quantities.
Successful implementation of iron fortification of wheat flour has been
achieved in several countries in the North America, Great Britain, South
America, and Caribbean.15
Another method is to fortify a widely consumed condiment such as
salt and sugar which have all been successfully fortified with iron. Both
dried and liquid milk and dairy products such as yogurt have been
fortified with iron in South America.
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In the control of iron deficiency anemia in children receiving
complementary foods, fortified infant foods are an especially important
component. This method has been shown to be effective in preventing
infant iron deficiency anemia in Latin America and United States.
In our country, this can be made possible by taking advantage of
existing technology and health care network.
National health programs:
IFA supplementation for children has been recommended by the
Ministry of health and family welfare. As part of this program, 20 mg
elemental iron and 100µg folic acid per mL of liquid formulation for
children aged 0 to 5 years and 30 mg elemental iron and 250 µg per day
in children aged 6 to 10 years, both for a period 100 days with age
appropriate deworming is recommended.
In the year 2013, a policy decision to develop the National Iron+
Initiative was taken by the Ministry of Health and Family Welfare.
Existing national programs were brought together under this initiative and
new age groups were introduced as given below.1
? Preschool children aged 6 months to 5 years are given iron
supplementation of 20 mg elemental iron and 100 µg folic acid bi-
weekly.
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? Children from 1st to 5th grade (5 to 10 years of age) in Govt. &
Govt. Aided schools are given weekly iron supplements containing
45 mg of elemental iron and 400 µg of folic acid by school
teachers. Out of school children are given iron supplements at
Anganwadi Centers.
? In the case of adolescents (10–19 years), weekly iron
supplementation is given containing 100 mg elemental iron and
500 µg of folic acid through school teachers.
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REVIEW OF LITERATURE
2.1. Articles related to prevalence:
In the year 2011, Sudhagandhi et al. conducted a study among
school children aged 8 to 16 years of Kattankulathur, Tamil Nadu to
know the prevalence of anemia. A total of 900 children were included in
this study and it was found that 52.88% were anemic and the prevalence
of anemia among girls (67.77%) was significantly higher when compared
to the boys (35.55%) and anemic children were underweight.21
Rayn et al., conducted a cross-sectional study in two rural districts
of Karnataka, in the year 2010 among children aged 12 to 23 months. Out
of the 401 children included in the study, anemia was detected in 75.3%
children. It was also found that low ferritin levels, maternal anemia and
food insecurity were associated with anemia. In this study, correlation
statistics revealed a direct association between children's ferritin levels
and their iron intake, CRP levels and the maternal hemoglobin levels. An
inverse association was also demonstrated between children’s ferritin
levels and history of continued breastfeeding and the child's energy
intake.22
A prevalence study was conducted by Sabitha basu among school
going adolescents girls of Chandigarh who were apparently healthy.
Results of the study revealed that anemia is more common among rural
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adolescents (25.4%) when compared to urban (14.2%) adolescents.  Also,
81.7% and 41.6% of the adolescent girls and boys respectively had
deficiency in Serum ferritin levels reflecting reduced iron stores.23
In the year 2010, a nationwide survey was done by Chellan et al.,
to  find  the  prevalence  of  anemia  and  to  assess  the  influences  of
socioeconomic and demographic factors on the degree of anemia. The
prevalence of anemia was high not only in the low socioeconomic group,
but also in the higher strata. But the percentage of severely anemic
children declined with mother’s educational level and standard of
living.24
Gomber et al., in Indian Journal of Medicine in October 2003
conducted a study in corporation schools among children of age 5 to 11
years from an urban slum and it was found that prevalence of anemia as
per WHO recommended cut-off values of hemoglobin  was 41.8 per cent.
The commonest type of anemia noted was pure or mixed iron deficiency
anemia in 68.42% children followed by pure or mixed B12 deficiency
noticed in 28.42% children. Iron deficiency was the commonest cause
among the pure variety occurring in 41.05 % (39 of 95) children.25
Duque et al. conducted a study among Mexican children aged less
than 2 years in rural as well as in urban areas to determine the prevalence
of anemia as well as deficiencies of iron, folic acid and zinc. In this study,
anemia was found in 20% of children. About 27.8% rural children and
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32.6% urban children in the study had iron deficiency. Low serum zinc
was noted in 28% urban and 13% rural children included in the study.
Similarly, folic acid deficiency was noted in 10% children in the urban
areas, and 8% children in rural areas. Thus, the principal micronutrient
deficiencies noted among Mexican children in the age group of less than
2 years was iron and zinc deficiencies. More important was the fact that
low ferritin concentrations were not seen in more than 50% of anemia.26
In January 2011, a study was done to determine the prevalence of
iron deficiency anemia by Al-Sayes et al. among apparently healthy
young female university students in Saudi and it was found that 50.2% of
students were normal and 25.9% of students had deficient iron store and
23.9% of students had iron deficiency anemia. There was a significant
correlation between iron deficiency and iron deficiency anemia with
inadequate meat intake and impaired exercise capacity.27
2.2. Articles related to clinical profile:
The study by Jain et al. among school girls of age 8 to 11 years in
2012 regarding correlation between hematological and cognitive profile
in  anemia  showed  that  among  111  children  in  the  sample,  77%  were
anemic with low iron studies ,lower IQ, intellectual capacity and
educational achievement than those of their non-anemic counterparts.
These three parameters had significant correlation (p<0.05) with Hb and
serum iron.28
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Lukowski et al. found that frontostriatal-mediated executive
functions like inhibitory control, set-shifting and planning were
performed less well by infants with chronic, severe iron deficiency. The
hippocampus-based recognition memory task was also impaired. These
deficits suggest that early iron deficiency in the long-term may affect the
hippocampus, dopamine system as well as their interaction.29
Peirano  et  al.  conducted  a  study  which  showed  affective
differences among infants with iron deficiency anemia. Also, infants with
iron deficiency anemia tested lower in mental and motor developmental
assessments. It was found that even after iron therapy, they had persistent
sleep disturbances and neurofunctional affects which lead to reduced
behavioral and cognitive outcomes indicating that iron may have key role
in the normal development and progression of several neurofunctional
systems.30
Fretham et al. published an article regarding the role of iron in at
least 3 major neurobehavioral domains in learning and memory, including
learning, speed of processing and affect. Learning and memory, being
particularly prominent, were affected by early life iron deficiency and
were found to persist despite iron repletion. In the case of adults,
interactions between direct and indirect effects of iron deficiency
contributing to abnormal hippocampal structure and plasticity is the likely
cause of learning deficits.31
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In the year 2014, the relationship between pagophagia (ice pica)
and iron deficiency anemia was studied by Uchida et al. Out of 81
patients with iron deficiency anemia, pagophagia was present in 13
patients (16.0%), and it was found that oral iron therapy can cure the
pagophagia earlier than hemoglobin recovery and repair of tissue iron
deficiency.32
2.3. Articles related to investigations:
Sazawal  et  al.  conducted  a  study  among 2091  children  in  the  age
group of 1–3 years from an urban low socio-economic population of
Delhi to determine the role of RDW in discriminating IDA and published
an article in the year 2014. The study found that in children with
hemoglobin values ?10.0 g/dL, RDW values greater than >15% identifies
iron deficient anemia without the need for iron status.33
In the year 2009, Aulakh et al. of Christian medical college,
Ludhiana conducted a study among 151 children aged 6 months-12 years
with microcytic (MCV<75 fL) anemia to determine the usefulness of Red
Cell  Distribution Width (RDW) for the diagnosis  of  iron deficiency.  On
the  basis  of  serum  ferritin  and  total  iron  binding  capacity  (TIBC),
Children with microcytic hypochromic anemia were classified into iron
deficient and non-iron deficient anemia. It was concluded that the RDW
had sensitivity and specificity of 81.0% and 53.4% respectively, in the
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diagnosis of IDA. Similarly, the positive and negative predictive value of
RDW in the diagnosis of IDA was 63.0% and 72.2% respectively.34
Lee et al., in 2001 investigated hematologic profiles of anemic
children aged 5 to 36 months (198 patients) comparing them with the
control group. The children were mainly brought to the clinic for
infectious or inflammatory illness. Only 13.1% children with iron
deficiency anemia had come directly for evaluation of pallor. Among the
children with IDA, the correlation between hemoglobin and MCV was
much more than the control group (P?0.001).  It was concluded in the
study that the accuracy of diagnosis of IDA can be increased by
combining hemoglobin, MCV, RDW as well as iron profile in screening
for iron deficiency.35
In the year 2014, the HELENA study conducted among adolescent
girls in 10 European cities to evaluate the usefulness of iron profile
confirmed that serum ferritin and serum transferrin receptors can be used
in assessing the iron status of adolescents and it was also found that
adolescent girls are at high risk of iron deficiency.36
2.4. Articles related to various iron therapies:
Aggarwal et al., in 2004 conducted a study among predominantly
breast fed term low birth weight (LBW) infants aged 50–80 days to
evaluate the hematological effects of iron supplementation. Total 73
58
infants enrolled were randomized into two groups. One group received
iron (3 mg/kg/day) and the other group received placebo drops. Baseline
anthropometry and hematological parameters were measured. These
measurements were repeated after four and eight weeks and no significant
differences were found in serum ferritin and anthropometry. However,
there was a significant positive change in hemoglobin levels in the iron
supplementation group.37
In 2004, a review article published in Indian Pediatrics regarding
iron supplementation recommended oral iron for treating iron deficiency
anemia. According to the article, the type of iron salt to be used has to be
based  on  the  bioavailability  of  the  iron  salt,  side  effects  and  cost
effectiveness.38
Ferrous salts, specifically ferrous sulfate, are preferred for
treatment of IDA, since all iron needs to be reduced to ferrous form for
absorption. As ferrous sulfate is not stable in liquid form, other ferrous
salts are used in liquid formulations. One important side effect of ferrous
sulfate is gastrointestinal intolerance. Various measures have been
suggested to overcome this side effect. These measures include
administration after meals and at bed time, since decreased intestinal
motility during sleep may help improve absorption.
59
In the case of ferric salts, ferric ammonium citrate is used. The
important drawback of these salts is the low bioavailability which is
considered to be 3-4 times less than ferrous salts.
Better bioavailability is claimed with iron-amino acid chelators,
which are other group of iron preparations, because absorption of this salt
is  said  to  be  not  interfered  by  phytates  in  the  diet.  However,  when
compared to ferrous sulfate in clinical studies in young children and
infants, equal rise in hemoglobin has been reported.
Iron polymaltose complex (I-PMC) and carbonyl iron are two more
types of iron preparations that deserve mention. The bioavailability of
iron polymaltose complex (I-PMC) has been demonstrated to be similar
to ferrous sulfate. Also, both ferrous sulfate and I-PMC in equivalent
doses were found to have similar efficacy in a recent meta-analysis on
iron polymaltose complex use in adults with IDA.
In the case of carbonyl iron, the main advantages are the small
particle size of the molecule contributing to increased bioavailability as
well as the considerably higher doses of administration. However, this
fact needs further research as the result of two Indian studies are
conflicting, one stating that the bioavailability to be higher and another
study finding the bioavailability to be similar. Carbonyl iron has been
mainly used in food fortification industry.
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Conventionally, a dose of 4-6 mg/kg/day of elemental iron were
recommended for treatment of IDA in children. However, it was found
that smaller doses were also equally effective as well as better tolerated.
Hence, currently a dose of 3 mg/kg/day of elemental iron is
recommended. It is to be noted that approximately 25 mg of elemental
iron saturates the absorptive capacity of iron in the duodenum. Therefore,
absorption of iron will not be increased at higher doses.
Low et al. in a meta-analysis of randomized controlled trials on the
effects of daily iron supplementation in 5-12 years old primary school
children identified 16501 studies in which a total of 7089 children were
evaluated. A total of 31 studies had been conducted in low or middle
income settings. The review concluded that there was improvement in
intelligence quotient (p = 0.04), global cognitive scores (p = 0.01) as well
as measures of attention and concentration among anemic children on
iron supplementation.39
An improvement in age-adjusted height and weight among anemic
children on iron supplementation was also noted. According to this
review, the risk of iron deficiency and iron deficiency anemia were 50%
and 79% respectively by iron supplementation.
Desai et al. conducted a study in Western Kenya among children
less than 2 years living in a malaria-endemic area, comparing the efficacy
of supervised as well as unsupervised, daily and twice weekly iron
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supplementation  over  a  period  of  6  weeks  in  the  treatment  of  mild  and
moderate anemia after administering a single dose of sulfadoxine-
pyrimethamine at enrollment. Daily supervised or unsupervised iron
supplementation was given in the dose of 3–6 mg/kg/day and twice
weekly supervised or unsupervised iron supplementation was given in the
dose of 6–12 mg/kg/wk.40
Results from the study revealed that hemoglobin concentration in
the daily supervised iron supplementation group was significantly higher
than twice weekly supervised iron supplementation group. In case of
unsupervised iron supplementation groups, hemoglobin concentrations
were significantly higher at 12 weeks. But, the hemoglobin
concentrations were not different at 6 weeks of iron supplementation.
It was concluded that, in the treatment of anemia in preschool
children, regardless of compliance to therapy, hematological responses
can be expected after 6 weeks of daily iron supplementation rather than
twice weekly iron supplementation.
2.5. Articles related to treatment and improvement in hemoglobin:
Maheswari et al. conducted a study among a total of hundred
anemic school children from three government schools of Raipur city.
They were subjected to anthropometry, iron status and clinical
examination before they underwent iron therapy and the response to iron
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was assessed by estimation of hemoglobin after one month following iron
therapy. In all the 100 children, clinical pallor was the most common
finding (100%), followed by fatigue (54%), weakness (38%), anorexia
(18%) and icterus (5%). The commonest blood picture was that of
microcytic hypochromic.41
Age  dependent  MCV,  MCH,  MCHC  and  RDW  showed  that  the
maximum  number  of  cases  had  below  normal  MCV,  MCH  and  MCHC
values. RDW values were increased in 74% cases. 82% cases had serum
iron values below normal (<50?g/dl) and 91% cases had TIBC values
above the normal range. The serum ferritin levels in 35% children was
<15ng/ml (in 18% boys and in 17% girls). The mean and SD of Hb
before therapy was 8.60 ± 2.05 and after therapy, it was 9.55±1.88
respectively. A significant increase in the hemoglobin (p<0.009) level
was observed in both boys and girls after 30 days of iron
supplementation.
A systematic review of randomized controlled trials in 2007
showed the effect of iron supplementation on hemoglobin response in
children by Gera et al. He found that there is significant, but modest
increase hemoglobin levels after iron supplementation. The review also
concluded that children who were anemic at the beginning of the trial
showed a greater increase in hemoglobin, whereas improvement in
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hemoglobin was much lower in those children living in malarial hyper-
endemic areas and in those consuming iron-fortified food.42
In  the  year  2010,  Huang  et  al.  in  Taiwan  conducted  a  study  to
determine the various causes of iron deficiency anemia and the treatment
outcomes. It was found that the most common cause in children less than
2 years was inadequate intake and blood loss was common in children
aged 2 to 10 years. Treatment with iron supplementation for 3 months
resulted in improvement of hemoglobin levels in 78.9% of IDA
patients.43
Paracha et al. conducted a study to determine the effects of iron
supplementation on iron status in selected pre-adolescent school girls
aged 8 to 11 years in North West Frontier Province, Pakistan by dividing
them into treatment and control groups. The treatment group received 76
mg elemental iron per day over a period of 11 weeks. At the same time,
both the groups received multivitamin tablets daily. It found that the 35%
of the pre-adolescent schoolgirls had IDA. The improvement in
hemoglobin (15g/dL), Hct (3%) and serum ferritin (20ng/mL) was
significant (P<0.05) in the anemic treatment group when compared to the
control group.44
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STUDY JUSTIFICATION
3.1. Study justification:
Iron deficiency anemia is most prevalent among nutritional anemia
and  it  constitutes  more  than  70%.  Though  there  are  many  studies  on
prevalence in rural and in varied populations and in schools, the present
study is done to assess the prevalence and profile of iron deficiency
anemia among the children of working group mothers. Though children
attending the ESI HOSPITAL belong to parents who are educated and are
aware of nutritional importance of minerals, most of them are not able to
take care of their children because of the work and hence my study is
done to assess the clinical profile in this particular population, and also to
test the correlation of various red cell indices with iron studies. Though
there are lot of studies on   iron   therapies   and comparison of various
formulations there are not many studies on improvement in hemoglobin
or follow up studies after   oral iron supplementation. Hence, this study is
intended to follow up children with iron deficiency  anemia to know the
improvement in hemoglobin.
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AIMS AND OBJECTIVES
4.0. Aim of the study:
The aim is to study the profile of nutritional anemia in children and
to determine the treatment outcome of iron deficiency anemia.
4.1. Objectives:
? To assess the proportion of various types of anemia like microcytic
hypochromic, normocytic hypochromic, normocytic normochromic or
megaloblastic anemia.
? To analyze the various presenting symptoms in relation to anemia
? To assess the correlation of Red cell indices and peripheral smear
with iron profile, folic acid and vitamin B12.
4.2. Secondary objective:
? To determine the treatment outcome of iron deficiency anemia in
children after oral iron supplementation for 12 weeks.
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MATERIAL AND METHODS
5. Material and methods:
Study design:
Cross-sectional study and interventional study
Place of study:
ESIC Medical College & PGIMSR, KK Nagar, Chennai
Period of study:
9 months
Sample size:
150 children
5.1. Inclusion criteria:
Children in the age group of 1 to 10 years with hemoglobin levels
less than the cut-off values for the age, as per WHO guidelines, were
included in the study. Out of the 150 children, those with iron deficiency
anemia were followed up for treatment outcome after iron therapy.
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5.2. Exclusion criteria:
? Chronic diarrhea
? Children with renal disease
? Children with cyanotic heart disease
? Children with endocrine diseases
5.3. Methods:
150 children in the age group of 1 to 10 years with pallor were
confirmed to have anemia by hemoglobin estimation.45, 46 The criteria for
diagnosing anemia was hemoglobin values less than 11 g/dL in children
aged 12 months to 59 months, less than 11.5 g/dL in children aged 5 years
to 11 years. Children who fulfilled the criteria were included in the study
after obtaining informed written consent from their parents.
Fig. 2 IMNCI guidelines for assessment of pallor45
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The history and examination was documented on a pre-designed
proforma. A social demographic profile including parents’ education,
family structure and diet consumed (vegetarian, non-vegetarian) was
noted. A detailed general physical examination was done to look for
pallor, icterus, edema, lymphadenopathy, and signs of vitamin deficiency.
The anthropometric measurements (weight, height) were made by a
single observer and finally, a thorough systemic examination was also
done.
The following investigations were done in all cases – complete
blood count, red cell indices, peripheral smear study, reticulocyte count,
RDW, ESR, CRP, stool for occult blood, serum ferritin, iron indices,
vitamin B12 and folic acid assay.
Children with iron deficiency anemia were given oral iron syrup
(iron polymaltose complex) in the dose of 3 mg/kg/day once daily, for 3
months and hemoglobin levels were checked at 1 and 3 months after
starting iron supplementation. Reticulocyte count was also checked after
one month of therapy.
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Blood sampling:
Blood samples were collected under strict aseptic precautions.
About 2 mL of blood was collected in EDTA tube for complete blood
count and peripheral smear examination. Around 3 mL of blood was
collected in 2 separate serum containers. One container was used for
spectrophotometric assay of serum iron and TIBC and the other container
for  assessment  of  serum  Ferritin,  Vitamin  B12  and  folic  acid  by  chemi
luminescent assay
Stool sampling:
Patient was instructed to eat a well-balanced diet including fiber
such as bran, cereal, fruits and vegetables. Red meat and excess of
vitamin C and iron supplements in excess of 250mg per day was avoided
3 days before collection of sample.
5.4. Laboratory techniques:
Complete blood count was done using five part automated cell
counter from Beckman Coulter with tri level Quality control from Bio-
Rad for measuring the following values such as hemoglobin, red cell
count, white cell count, PCV, MCV, MCH, MCHC and platelet count. A
peripheral blood smear was prepared, stained using Leishman stain and
examined under the microscope. Reticulocyte count was calculated
manually after supravital staining.
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The ferritin assay was done by using the technique of
chemiluminescent immunoassay on Access 2 equipment from Beckman
Coulter in human serum using monoclonal anti ferritin antibodies.
Serum iron and serum unsaturated iron binding capacities (UIBC)
were quantitatively determined on Roche/Hitachi cobas c 311 systems
using spectrophotometric immunoturbidimetric assay. TIBC was derived
from  the  sum  of  serum  iron  and  UIBC.  Serum  transferrin  and  serum
transferrin saturation are derived values from serum iron and TIBC.
Vitamin B12 and serum folate were also determined using
chemiluminescent immunoassay.
Erythrocyte sedimentation rate was estimated by automated infra-
red based machines using Westergrens method. The C-reactive protein
was determined in human serum done by immunoturbidimetric assay on
Roche/Hitachi cobas c 311 systems.
Stool samples were tested for occult blood by hemospot test.
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STATISTICAL ANALYSIS
6. STATISTICAL ANALYSIS
In the above study, the statistical methods used for quantitative
data were descriptive statistics presented by N, Mean, Standard Deviation
and Range. For qualitative data, frequency count, N and percentage were
put in tabular columns.
To analyze the data, appropriate statistical tests were applied. To
compare the difference between variances in the subjects, one way
ANOVA was used. To find the correlation between hemoglobin, red cell
indices & iron profile, Pearson’s correlation coefficient was used.
All the statistical analysis had been done by using statistical
software SPSS (version 16.0). Other data are displayed by various tables
and charts by using Microsoft excel (windows 7).
* Significant at p < 0.05
**   Very significant p <0.01
***  Highly significant p < 0.001
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RESULTS
7. RESULTS
A total of 150 children were enrolled as study population  and
statistical analysis revealed the following observations.
Demographic profile:
Fig. 7.1 Age distribution of children
Among the 150 children, 66.7% (n= 100) were between 1 to 5
years of age and 37.3% ( n=50 ) were between 5 to 10 years of age. The
mean age of children with microcytic hypochromic anemia (MHA),
normocytic hypochromic (NHA), and normocytic normochromic anemia
(NNA) was 3.39 years ± 2.75, 5.2 years ± 3.67 and 5.05 years ± 3.22
respectively.
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Fig. 7.2 :  Age distribution among various types of anemia
77
Fig. 7.3 : Mean age among various types of anemia
In children with  MHA, 80% (n=44) were in the age group of 1 to 5
years and 20% (n=11) were in the age group of 5 to 10 years. In children
with NHA and NNA, 53.30% (n=7) and 58.80% (n=48)  were between 1
to 5 years of age respectively. Among 5 to 10 years age group, the
children with NHA were 46.70% (n=8) and the children with NNA were
40% (n=32).
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Fig. 7.4: Sex distribution of children
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Fig. 7.5:  Sex distribution among various types of anemia
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Table 7.1. Sex distribution among various types of anemia
Gender
MHA NHA NNA
N % N % N %
Female 22 40.00% 4 26.70% 33 41.20%
Male 33 60.00% 11 73.30% 47 58.80%
Among the study population, 60.7% (n=91) were male and 39.3%
(n=59) were female. In the study group with  MHA, 60% (n=33) children
were  males  and  40%  (  n=22)  were  females.  In  children  with  NHA,
73.30% ( n=11) were male and 26.70% ( n=4) were female. In children
with NNA, 58.80% (n=47) were male and 41.20% (n=33) were female.
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Fig. 7.6: Socioeconomic status of the families
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FIG. 7.7: Prevalence of anemia in various socioeconomic classes
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The socio-economic status of the children was assessed by
modified Kuppuswamy’s scale47 and  it  was  found  that  majority  of  the
families belonged to class II   [  68.7% (n=103) ]  followed by class III   [
28.7% (n=43) ] and class IV [ 2% (n=3) ] and class I [ 0.7% (n=1) ]
On analysing the socioeconomic class in children with MHA, it
was found that 78.20% (n=43) belonged to class II socioeconomic status
and 21.80% (n=12) belonged to class III.
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Fig. 7.8:  Dietary habits of families
Majority of the families consumed non-vegetarian diet [82.7%
(n=124)] and only 16.7% (n=26) consumed vegetarian diet.
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Fig. 7.9:  Gestational age at birth
Out of the 150 children included in the study, 11.3% children were
born preterm (n= 17) and the rest were born at term gestation.
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Fig. 7.10:  Duration of exclusive breastfeeding
It was found that 53% (n=79) of the children were exclusively
breast  fed  up  to  6  months.  In  26%  (n=39)  of  children  exclusive  breast
feeding was practiced only up to 4 months. In 12% (n=18) of cases,
exclusive breastfeeding was given for more than 6 months. In 8.7%
(n=13) of children exclusive breastfeeds were received only up to one
month.
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Fig. 7.11:  Time of introduction of artificial feeding
Early cow’s milk/formula feeds were started in 26% (n= 32) of
children between 1 to 4 months and 29% (n=36) between 4 to 6 months
and 34% (n= 42) between 6 to 12 months. In 4.9% of children, artificial
feed was introduced in the first month of life.
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Fig. 7.12:  Time of introduction of complementary feeding
Majority of the children (58.6 %) received early complementary
feeding by 4 to 6 months and in 26.6% , the children received
complementary feeding between 6 to 10 months.
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Fig. 7.13:  History related to anemia
History  of  worm  infestation  was  present  in  42.7%  (n=64)  of
children, pica in 35.3% (n=53), pagophagia in 12.5% (n=19), past
infections in 28.7% (n=43), Gastrointestinal bleed in 4% (n=6), family
history of hemolytic anemia in 2% (n=3) and drug intake in 0.7% (n=1)
of children.
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Fig. 7.14:  Proportion of anemic children having pica
Pica was found to be more in children with MHA constituting
47.30% (n=26).
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Fig. 7.15:  Symptoms of anemia
Symptom analysis revealed that majority of children had lethargy
which was found in about 47.3% (n=71 ) followed by easy fatigability in
41.3% (n=62), irritability in 25.3% (n=38), poor school performance in
20.7% (n=31), breathlessness in 7.3% (n=11), headache and dizziness in
2.7%  (n=4)  and  2%  (n=3)  respectively  with  palpitation  and  chest  pain
accounting for the least number in about 1.3% (n=2).
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Fig. 7.16 Symptom analysis among various groups of anemia
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Table 7.2 Symptom analysis among various groups of anemia
Types of anemia MHA NHA NNA
Symptom N Mean N Mean N Mean
Irritability 19 34.50% 4 26.70% 15 18.80%
Lethargy 30 54.50% 6 40.00% 35 43.80%
Poor school
perfomance
7 12.70% 2 13.30% 22 27.50%
Easy fatigability 23 41.80% 5 33.30% 34 42.50%
Among the 150 children with various types of anemia, irritability [
34.50 % (n=19)] and lethargy [ 54.50% (n=30)] was more in children
with MHA.
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Fig. 7.17:  Signs of anemia
Among the 150 children examined, leuconychia was present in
33.3% (n=50), koilonychia in 32% (n=48), generalized lymphadenopathy
in 23.3% (n=35). Cheilitis, glossitis, hepatosplenomegaly was found in
14% (n=21), 12% (n=18) and 10% (n=15) respectively.
95
Fig. 7.18:  Proportion of various types of anemia
It was noted from our observation that among the 150 children,
36.7% (n=55) had microcytic hypochromic anemia, 10% (n=15) had
normocytic hypochromic anemia and 53.3% (n=80) had normocytic
normochromic anemia.
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Fig. 7.19: Descriptive statististics of CBC profile
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Table 7.3  Mean values of red cell indices
Types of anemia MHA NHA NNA
Hb 8.22 ? 1.27 9.58 ? 0.91 9.925 ? 0.91
PCV 28 ? 9.22 31.43 ? 3.58 32.33 ? 3.58
MCV 59.1 ? 12.30 70.29 ? 7.06 73.98 ? 10.44
MCH 19.33 ? 5.96 21.39 ? 1.94 23.53 ? 2.95
MCHC 35.08 ? 36.18 34.1 ? 13.5 31.31 ? 2.50
Statistical analysis of complete blood count reveals the mean Hb is
8.22 ? 1.27 in children with MHA and in children with NHA and NNA,
the mean Hb is 9.58 ? 0.91 and 9.925 ? 0.91 respectively. The mean
values of  PCV, MCV, MCH, are less in MHA when compared to NHA
and in NNA.
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Fig. 7.20:  Scatter plot diagram showing correlation between
hemoglobin and RDW
The mean RDW in children with MHA was 16.75 ? 3.96, 14.61 ?
2.44 in NHA and 14.50 ? 2.93 in NNA. The scatter plot diagram shows
that, in our study, the red cell distribution width increases as hemoglobin
values decrease.
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Fig. 7.21:   Descriptive statistics of iron profile
100
Table 7.4   Mean values of iron profile
Types of anemia MHA NHA NNA
S. Iron (?g/Dl) 31.62 ? 23.90 46.22 ? 23.40 51.64 ? 22.52
TIBC (?mol/L) 392.82 ? 103.7 359.96 ? 79.11 315.8 ? 81.36
S. Transferrin
(mg/dL)
424.44? 90.45 406.17 ? 83.63 367.44 ? 77.38
Transferrin
saturation (%)
8.76 ? 11.25 11.45 ? 5.71 14.68 ? 7.63
S. Ferritin (ng/mL) 38.84 ? 49.75 69.97 ? 138.01 91.93 ? 203.90
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The descriptive statistics of iron profile revealed that the mean
serum iron levels were 31.62 ?  23.90  ?g/dL  in  children  with  MHA,
46.22 ? 23.40 ?g/dL in children with NHA and 51.64 ? 22.52 ?g/dL in
children  with  NHA.  The  mean  TIBC  was  increased   in  children  with
MHA with a mean of 392.82 ? 103.7 ?mol/L, and in children with NHA,
the mean TIBC is 359.96 ? 79.11 ?mol/L, and in NNA , the mean is
315.8 ? 81.36 ?mol/L. Serum transferrin was high in children with MHA
and in children with NHA, the mean transferrin levels were low when
compared to MHA. The mean serum ferritin levels were 38.84?  49.75
ng/dL in children with MHA and in children with NHA the mean levels
were 69.97 ? 138.01 ng/dL, and 91.93 ?  203.90 ng/dL respectively.
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Table 7.5 Pearson’s correlation statistics between hemoglobin, red
cell indices and iron profile
Pearson
Correlati
on
PCV MCV
MC
H
MCH
C
RD
W
S.
Iro
n
TIB
C
Transf
er. Sat
S.
Transfer
rin
S.
Ferrit
in
Reticuloc
yte count
Hemoglo
bin
.366
**
.316
*
.308
* 0.225
-
.287
*
0.25
9
-
0.22
8
0.188 -0.193 0.125 -0.072
P value 0.006
0.01
9
0.02
2 0.099
0.03
4
0.05
7
0.09
4 0.169 0.158 0.362 0.603
On analyzing  the  data  of  MHA with  Pearson  correlation  statistics
of hemoglobin and red cell indices, it was found that hemoglobin had
weak positive correlation with PCV, MCV, MCH and weak negative
correlation with RDW. The correlation is at p<0.05 level significance.
Hemoglobin has weak correlation with iron studies and it is not
statistically significant.
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Table 7.6 Comparison of mean differences between 3 groups of
anemia
ANOVA test
Types of
anemia
MHA NHA
NNA
Sig
Parameters Mean SD Mean SD Mean SD p value
Hemoglobin 8.23 1.27 9.58 0.76 9.93 0.91 0.0001***
PCV 28.00 9.23 31.43 3.59 32.33 3.90 0.0001***
MCV 59.10 12.30 70.29 7.07 73.98 10.44 0.0001***
MCH 19.33 5.97 21.39 1.94 23.53 2.95 0.0001***
MCHC 35.09 36.18 34.10 13.52 31.32 2.50 0.617
RDW 16.75 3.96 14.61 2.44 14.50 2.93 0.001**
Reticulocyte
count
1.08 1.19 0.55 0.26 0.84 0.36 0.045*
S. Iron 31.62 23.90 46.22 23.40 51.65 22.52 0.0001***
TIBC 392.82 103.70 359.96 79.11 315.80 81.36 0.0001***
Transferrin
saturation
8.76 11.25 11.46 5.71 14.68 7.63 0.001**
S.
Transferrin
424.44 90.45 406.18 83.63 367.45 77.38 0.001**
S. Ferritin 38.84 49.75 69.98 138.01 91.93 203.90 0.164
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One way ANOVA test was used to compare the differences in
mean of various indices among the children with MHA, NHA and NNA.
The mean difference between groups with respect to hemoglobin, PCV,
MCV, MCH and RDW was statistically highly significant (p=0.0001).
The reticulocyte count also was compared and the difference was
statistically significant (p = 0.045). It is seen from the table above that the
mean difference in serum ferritin levels (p=0.164) and MCHC (p=0.617)
was not statistically significant between the groups.
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Table 7.7 Comparison of serum ferritin, ESR and CRP between the
groups
Types
of
anemia
S. Ferritin ESR CRP
Values < 15ng/mL
>15
ng/mL
< 20
mm/Hr
>20
mm/Hr
<10
mg/L
>10
mg/L
MHA
26
(47.27%)
29
(52.72%)
29
(52.72%)
26
(47.27%)
35
(63.63%)
20
(36.36%)
NHA
4
(26.6%)
11
(73.33%)
8
(53.33%)
7
(46.67%)
8
(53.33%)
7
(46.67%)
NNA
17
(21.25%)
63
(78.75%)
37
(46.25%)
43
(53.75%)
43
(53.75%)
37
46.25(%)
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Table 7.8 Proportion of cases with elevated ESR/ CRP and normal
serum ferritin levels
Types of anemia ESR CRP
MHA 15 (51.7%) 10 (34.48%)
NHA 5 (45.45%) 3 (27.27%)
NNA 38 (60.3%) 31 (49.20%)
From the previous observations, it was obvious that serum ferritin
was not reduced in all children with anemia. Hence, the correlation with
ESR  and  CRP  was  done  and  it  revealed  that  out  of  29  children  with
MHA, 15 had elevated ESR and 10 children had elevated CRP. In NHA,
5 out  of  11 children and in NNA, 38 out  of  63 children had increase in
ESR. In NHA, 3 out of 11 and 31 out 63 had increased CRP levels.
A total of 7 out of 29 children with MHA had elevations in both
ESR and CRP and 3 out 11 children with NNA and 24 out of 63 children
also had elevations in both ESR and CRP.
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Treatment outcome (n=50):
Out  of  the  150  children,  a  total  of  55  children  had  MHA.  These
children were given oral iron supplementation and were followed-up. 5
children were lost to follow-up. The results of the follow-up are shown
below.
Fig. 7.22:  Improvement in hemoglobin after iron therapy
The follow-up study after oral iron supplementation had shown that
the mean hemoglobin increased from the baseline value of 8.25 ? 1.302
mg/dL to 9.17 ?  1.365 mg/dL after one month and it increased to 10.38 ?
1.368 mg/dL after 3 months.
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Table 7.9 Follow-up hemoglobin and its significance
Paired Samples Test
Parameters
Paired Differences 95% Confidence interval of the Difference
Mean Std.Deviation
Std.
Error
Mean
Lower Upper t testvalue df p value
Hb level -
Baseline and
follow-up
after 1
month
-0.916 1.100 0.156 -1.229 -0.603 -5.888 49 0.0001***
Hb level -
Baseline and
follow-up
after 3
months
-2.126 1.277 0.181 -2.489 -1.763 -11.771 49 0.0001***
Hb level
after 1
month  and 3
months
follow-up
-1.210 0.651 0.092 -1.395 -1.025 -13.137 49 0.0001***
Reticulocyte
count  -
Baseline and
follow-up
after 1
month
-0.272 1.232 0.174 -0.622 0.077 -1.56 49 0.125(NS)
*** Highly Significant, NS-Not Significant
The mean increase in hemoglobin at 1 month from baseline month
and then at 3 months was statistically significant (p=0.0001).
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Table 7.10 Improvement in reticulocyte count after one month
Corrected
reticulocyte
count
Mean Std. deviation Std. error
Baseline 0.729 0.610 0.086
Follow-up after 1
month
1.001 0.968 0.137
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Fig 7.23 Mean increase in reticulocyte count after treatment
It is seen from the observation that the corrected reticulocyte count
has increased from the baseline of 0.7 to 1.0.Though there is an increase
in reticulocyte count it has not shown any statistical significance
(p=0.125).
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DISCUSSION
This  study  was  primarily  designed  to  determine  the  clinical  and
laboratory profile of nutritional anemia among children attending the
Pediatric outpatient Department of a tertiary care hospital.
A total of 150 children were recruited, following confirmation of
anemia with hemoglobin estimation. After a targeted history and detailed
clinical examination, they were subjected to red cell indices and iron
studies besides RDW, reticulocyte count and peripheral smear. Serum
vitamin B12 and folic acid levels were estimated in all cases. An attempt
was also made to look for laboratory evidence of inflammation by
estimating ESR and CRP in all cases.
Based on the above investigations, anemia was grouped into
microcytic hypochromic anemia (MHA, 55cases), normocytic
hypochromic anemia (NHA, 15 cases) and normocytic normochromic
anemia (NNA, 80 cases). There were no cases of macrocytic anemia on
peripheral smear examination and serum B12 and folic acid levels were
normal in all cases.
On analyzing the group characteristics of MHA, it was found that
80% of the children belonged to a younger age group (1-5 years). A
similar observation was also noted in a study by Rayn et al. wherein 75%
113
of children with IDA were in the 1-2 years age group. However, there
was no statistically significant difference in gender distribution.
On the socio economic front, most of the cases belonged to a
relatively higher class (78% in Class II Kuppuswamy Scale). The
presence of anemia, in this socioeconomic group, is explained by the fact
that most of the mothers were working and hence the diet of the child
probably remained unsupervised. Chellan et al. also observed a greater
prevalence of anemia in higher socioeconomic strata.24
Worm infestation, which may have been a predominant contributor
to IDA, was seen in up to 44% of cases and pica was seen in 47.3% of
children with microcytic hypochromic anemia. Subjective symptoms
(lethargy, easy fatigability, irritability) were seen in 55% of cases
whereas objective symptoms like breathlessness and palpitations were
seen in very few. The absence of objective symptoms in our series is
presumably because of the lesser severity of anemia as evidenced by
mean hemoglobin of 8 g/dL. Maheshwari et al. had observed fatigue in
54% and weakness in 38% of their cases.41
Among  the  55  cases  with  MHA,  though  MCV  and  MCH  values
were suggestive of iron deficiency, serum ferritin values were normal in
53% of cases. This was similar to the observation made by Duque et al.26
where >50% children in the age group of 1-2 years had no correlation
between iron deficiency and serum ferritin levels. It was also seen that in
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the study conducted by Maheshwari et al. only 35% had low ferritin
levels.41
Ferritin  is  an  acute  phase  protein  that  rises  in  response  to
inflammation. The presence of normal ferritin in cases of IDA can be
explained by the fact that in a hospital based study like ours, subclinical
infection or latent inflammation could well be the cause for such an
elevation, thus masking the true size of the iron store.13 This association
with inflammation is also suggested by the elevated CRP in 36.36% of
cases and elevated ESR in 47.3%.When such confounders are
encountered; the estimation of RDW may help in identifying true IDA.
RDW is a quantitative measure of all the variation in the width of
the RBCs. It is of great value in discriminating IDA from other causes of
microcytic hypochromic anemia, but studies in children are few. Elevated
RDW (>15%) was seen in 67% of our MHA cases.  RDW was found to
have  a  strong  correlation  with  IDA  in  the  present  study.  In  studies  by
Sazawal et  al  and Aulakh et  al.  the sensitivity of  RDW was found to be
81% in diagnosing IDA.33,34
A  small  proportion  of  patients  (n=15)  with  NHA  are  probably
patients with evolving iron deficiency as the average MCH value in this
group was low at 21.9%. With time, these children would have evolved
into frank hypochromic, microcytic anemia. In a resource poor setting,
there is an urgent need to identify IDA in its earliest stage and replenish
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stores to prevent cognitive impairment and growth failure. Probably, this
group of children too will benefit from oral iron therapy.28
Among the 150 recruited cases, we were surprised to find that more
than half the children (80 cases) belonged to the category of normocytic
normochromic anemia, which is classically associated with chronic
disease, even though we did not include any cases with overt systemic
illness or inflammation in the study.13 Symptomatology of these cases
mimicked iron deficiency and the finding of pica and koilonychia in one-
third of the cases also prompted us to study the parameters in greater
detail. The ferritin levels were normal in the majority of this group (79%)
and low in only one-fifth of the cases.
Inflammatory disorders cause elevation of circulating hepcidin,
which causes a blocking effect on enterocytes and reticulo-endothelial
system leading to iron deficient erythropoiesis. Since hepcidin levels
cannot be assessed easily, an alternate and cheaper modality would be
needed.
A widely used and easily available marker of inflammation is the
CRP with values above 10 - 30mg/L being significant. On analysis of
cases of NNA with normal ferritin, it was found that 39% had elevated
CRP while 47% had increased ESR, again indicating transient infection
or inflammation being the triggering agents. Thus, in anemic children
with elevated CRP, concurrent iron deficiency must be considered despite
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high ferritin levels. In such situations increased RDW has been seen to be
a strong pointer towards iron deficiency.
In  our  study,  RDW  had  a  strong  correlation  with  anemia  in  only
35% of children with normocytic normochromic anemia. It is unlikely
that such a significant number of children would actually be suffering
from anemia of chronic disease. It is likely that such children too may
have latent iron deficiency anemia and it is this group that in a busy OPD,
may get overlooked. It is important to note that they too may benefit from
oral iron therapy and that further studies are needed to establish the same.
In terms of correlation of the hemoglobin with the red cell indices,
we found a positive correlation between hemoglobin and MCV and MCH
which was statistically significant and a statistically significant negative
correlation with the RDW. This has been borne out amply in many
studies wherein a high RDW has been found to be a sensitive marker of
iron deficiency.
Treatment and follow up:
All  cases  with  MHA  were  treated  with  iron  supplements  in
therapeutic doses and hemoglobin and reticulocyte count were repeated at
1 month followed by hemoglobin alone at 3 months after starting
treatment.
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There was an increase in reticulocyte count as well as hemoglobin
at 1 month follow up but the rise in the reticulocyte count was much
lower than the expected i.e. from a mean count of 0.7% to 1 %. The mean
increase in hemoglobin was only 2 g% over three months while the
expected rise is about 1 – 2 g% per month8. This was attributed to issues
related to compliance, GI intolerance and also to frequent inter current
infections necessitating temporary iron withdrawal. The studies done by
Maheshwari et al.41 and  Huang  et  al.43 showed that only 78.9% cases
improved with iron indicating that supplementation of a deficient nutrient
may not result in 100% improvement due to multiple confounders.
In summary, in our study we found a major percentage of children
with normocytic normochromic anemia rather than microcytic
hypochromic anemia. These cases, as discussed earlier, are presumably
cases with latent iron deficiency and will probably benefit with oral iron
therapy followed by a meticulous follow up to detect other disorders.
Though, in the formulation of the study design we had treated only
established  cases  of  MHA  with  iron  supplements,  the  finding  of  such  a
large number of children with NNA, makes us postulate that it would be
ideal  to  give  a  trial  of  oral  iron  to  this  group  also  and  then  estimate  the
response rather than go in for expensive investigations to definitely
establish other causes.
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Since the ferritin values were inconclusive in the diagnosis of
anemia,  it  may  not  always  be  useful  as  a  single  parameter  to  either
diagnose or exclude IDA. Probably RDW could have a better diagnostic
value in IDA. Larger studies comparing RDW with anemia are needed in
the future.
LIMITATIONS
1. Sample size should have been larger
2. The group with NNA and NHA could have been given a
therapeutic trial of iron in order to validate our postulate
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Conclusion
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CONCLUSION
1. In children with IDA, normal or high ferritin level should not
distract the physician away from the diagnosis as co-existing
infection and inflammation may confound the picture.
2.  In cases of normocytic, normochromic anemia, S. ferritin levels
can mask a latent iron deficiency. In doubtful cases a therapeutic
trial of oral iron is more cost effective. If red cell and iron indices
do not improve with an adequate trial of iron, it may be worthwhile
to go ahead with more sophisticated and expensive investigations
to find alternate causes.
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1 Nithish 1.5 1--5 M 2 T Y 6 1.5 7 NV N N N Vfever N N N N N N N N N N N N 80 0.8 9.3 14.53 Y N N  N  N N N N N 9.5 9--11 12900 4.36 29.2 67 21.7 32 16.2 2.74 0.5 28.4 414 6.42 442.09 3.9 196 80.31 10 0.69 NNA N
2 Srikanth 7 5--10 M 2 T Y 6 0 6 NV N N N N N N N N N N N N N N N N 108 1.08 17.8 15.26 Y N N  N N N N N N 10 9--11 11700 4.42 33.2 75 22.7 30 16.1 2.2 0.8 34.36 310 9.98 344.16 31.9 315 4.67 31 13.08 NNA N
3 Mohammed Firadaus 5 1--5 M 2 T Y 6 17 6 NV Y N N N N N N Y N N N N N N N N 100 1 15 15.00 Y N N  N N N N N N 9 7--9 6000 5.24 29.4 56.2 17.7 32 15.6 4.06 0.5 115.6 152 43.25 267.19 131.9 651 15.92 59 1.04 MHA N 10.0 1.0 11.2
4 Sivasakthi 5 1--5 M 2 T Y 1 2 6 NV N N N N N N N N N N N N N N N N 109 1.09 15.2 12.79 Y N N  N N N Y Y N 6.6 >=7 7900 3.68 20.2 54.9 17.9 33 21.8 3.61 0.5 7.97 279 2.77 287.46 83.7 347 4.85 12 25.92 MHA N 7.1 0.3 8.8
5 Vaishali 2.5 1--5 F 2 T Y 5 12 5 NV Y Y N N N N N N N N N N N N N N 80 0.8 10 15.63 Y N N  N N N N N N 9.6 9--11 6600 4.57 31.1 68 21 31 15.7 3 0.6 53.97 350 13.37 403.56 7.1 325 11.13 9 3.37 NNA N
6 Logesh 1.5 1--5 M 3 T Y 10 12 10 NV N N N N N N Y N N N N N N N N N 80 0.8 10 15.63 Y N N  N N N N N N 10 9--11 11001 4032 32.7 75.7 24.9 33 14 3.63 1 87.65 327 21.13 414.88 23.6 937 25.2 31 3.11 NNA N
7 Tharani 2 1--5 F 3 T Y 5 5 9 NV N Y N Walri N N Y N N N N N N N N N 78 0.78 8.3 13.64 Y N N  N N N N N N 8 7--9 9000 4.31 25 57.9 18.6 32 19.6 2.79 1 21.75 424 4.88 445.79 25 200 180 43 6.27 MHA N 9.0 1.0 9.5
8 Mohan kumar 5.5 5--10 M 2 T Y 6 8 6 NV N Y N N N N Y Y N N N N N N N N 106 1.06 16.3 14.51 Y N Y N N N Y N N 7.1 7--9 5600 4.63 23.4 50.5 15.4 30 20.1 3.2 2 13.68 443 3.00 456.26 2.7 617 13.74 20 0.5 MHA N 8.8 0.7 10.5
9 Dhanshika 2 1--5 F 3 PT Y 6 0 6 NV N N N
Atypicalfe
brileillness N N N N N N N N N N N N 86.5 0.87 10.3 13.77 Y N Y N N N N N N 10.4 9--11 13600 4.74 31.3 66 22 33 18.2 3.6 1 29.31 394 6.92 423.4 37.4 270 11.97 41 6.31 NNA N
10 jayachandiran 2 1--5 M 3 T Y 6 7 6 NV N N N Vfever N N Y N N Y N N N N N N 85 0.85 9.93 13.74 Y N Y N N N N N N 9.8 9--11 9300 4.33 29.7 68.6 22.7 33 14.2 2.79 0.3 92.64 342 21.32 434.42 17.3 274 8.82 15 1.25 NHA P
11 vidharth 2 1--5 M 2 T Y 6 12 6 NV Y N N N N N N N N N N N N N N N 91 0.91 13.6 16.42 Y N N  N N N N N N 10 9--11 14400 5.76 38.5 66.8 20.4 31 15.1 2.72 0.1 79.62 410 16.25 490.02 13.7 194 14.78 13 0.24 NHA N
12 varnika 3 1--5 F 2 T Y 6 7 6 NV Y Y N N N N N N N N N N N N N N 90 0.9 13 16.05 Y N N  N N N N N N 8.1 7--9 8700 4.77 28.1 59 16.9 29 19.9 2.94 0.6 29.78 387 7.15 416.68 18.4 261 11.32 40 0.73 MHA N 9.1 0.8 9.7
13 Hariharan 2 1--5 M 2 T Y 6 7 7 NV Y N N loosestool N N N N N N N N N N N N 70 0.7 10 20.41 Y N N  N N N N N N 10 9--11 27000 4.83 29.2 60.4 20.8 35 16.9 3.13 0.6 49.7 292 14.54 341.9 12 386 11.25 50 10.36 MHA N 9.6 1.4 10.6
14 Sangeetha 8 5--10 F 3 T Y 9 9 9 NV N N N Vfever N N N N N Y N N N N N N 180 1.8 17.8 5.49 Y N Y N N N N N N 9.8 9--11 11300 3.67 28.1 77.4 26.6 34 12 1.69 0.9 78.26 214 26.80 292.06 47 185 17.92 84 14.07 NNA N
15 Masthan 1.5 1--5 M 2 T Y 6 7 7 NV N N N loosestool N N N N N N N N N N N N 78 0.78 8.7 14.30 Y N N  N N N N N N 10.2 9--11 15800 5.33 35.2 66 19.1 29 22.7 3.96 0.5 49.44 375 11.64 424.63 10.9 635 10.96 1 0.75 NNA N
16 Santhosh Raj 2 1--5 M 3 T Y 8 9 9 NV Y Y N loosestool N N Y N N N N N N N N N 75 0.75 9.2 16.36 Y N N  N N N N N N 7.6 7--9 18600 4.87 25.4 52.2 55.6 30 19.6 4.8 2 20.94 435 4.59 455.81 2.2 269 5.38 10 6.53 MHA N 7.9 1.0 8.5
17 Mohammed haroon 1.4 1--5 M 2 T Y 3 7 3 NV N N N N N N N N Y N N N N N N N 83 0.83 11.5 16.69 Y N N  N N N N N N 9.8 9--11 32900 3.63 28.3 77.8 26.9 35 12.5 2.57 1.5 63.81 242 20.90 305.35 20.12 562 12.15 12 27.34 NNA N
18 Keerthirajan 3 1--5 M 2 T Y 5 12 6 NV N N N N N N N N Y N N N N N N N 97 0.97 16.1 17.13 Y N Y N Y N N N N 9.9 9--11 5700 4.13 30.6 74 22.1 30 12.9 2.47 0.8 24.64 306 7.45 330.93 62.8 325 17.24 62 9.88 NNA N
19 Rithikagowda 2.9 1--5 F 2 T Y 1 2 6 NV Y N N N N N N N N N N N N N N N 92 0.92 11.4 13.47 Y N Y N N N N N N 10.8 9--11 23600 4.59 32.1 70 23.5 34 15.3 2.65 1 16.93 299 5.36 315.73 76.1 315 17.04 28 77.19 NNA N
20 jonathan samuel 1 1--5 M 2 T Y 6 0 7 NV N N N UTI N N N Y N N N N N N N N 75 0.75 8.48 15.08 Y N N  N N N N N N 9 7--9 13800 4.22 21.3 64.6 21.3 33 14 6.8 0.6 20.38 429 4.53 449.76 16.9 211 22.43 68 57.03 NNA N
21 Gokulnath 2 1--5 M 2 T Y 3 4 6 NV N N N N N N N N N N N N N N N N 87 0.87 11.1 14.67 Y N Y N N N N N N 8.8 7--9 11800 4.29 26.5 61.8 20.5 33 17.6 2.75 0.4 20.99 301 6.52 321.99 65 325 17.82 25 224.47 NHA N
22 Chandreleka 2 1--5 F 3 T Y 8 9 10 NV N N N N N N N N N N N N N N N N 84 0.84 9.7 13.75 Y N Y N N N N N N 10 9--11 14500 4.64 31.2 67.1 22.9 34 19.4 5.82 1 47.94 440 9.83 487.89 48 173 13.68 8 0.27 NNA N
23 Goutam 9 5--10 M 2 T Y 4 8 4 NV Y N N N N N N N Y Y N N N N N N 120 1.2 25.8 17.92 Y N N  N N N N N N 9.6 9--11 13400 4.46 29.3 65.7 21.6 33 12.1 4.86 0.6 14.77 433 3.30 447.77 3.7 483 5.27 21 1.25 NHA N
24 Harini 1.6 1--5 F 2 T Y 6 6 7 NV N Y N N N N N Y N N N N N N N N 71 0.71 7.12 14.12 Y N N  N N Y N N N 8.1 7--9 12900 4.71 28.2 59.9 17.3 29 15.3 5.5 1 22.07 526 4.03 548.07 2.12 275 9.75 12 3 MHA N 9.2 0.8 10.0
25 Roshan 1 1--5 M 3 T Y 6 0 6 NV N N N N N N N N N N N N N N N N 70 0.7 8.6 17.55 Y N N  N N N N N N 8.9 7--9 11100 3.67 26.7 72.8 24.3 33 12.9 3.5 5 54.38 386 12.34 440.57 2.19 492 17.82 11 0.44 MHA N 10.6 1.0 11.9
26 Govardha harini 2.5 1--5 F 2 T Y 0.1 5 6 NV Y Y N N N N Y N N Y N N N N N N 94 0.94 12.7 14.37 Y N N  N N N N N N 8.6 7--9 13300 4.81 27.6 57.3 18.7 33 15.5 3.6 1 34.47 543 5.97 577.73 75 512 14.04 28 0.13 MHA N 10.8 0.8 11.9
27 Yuvashree 4 1--5 F 2 T Y 6 8 6 NV Y N N Vfever N N Y Y Y N N N N N N N 93 0.93 10.7 12.37 Y N Y N Y N N N N 9 7--9 11400 4.96 27.9 56.3 18.3 32 22.4 4.05 1 28.84 406 6.63 434.83 52 522 15.5 25 3.45 MHA N 10.5 0.6 11.8
28 Varshini 6 5--10 F 2 PT Y 2 2 6 NV Y N N Vfever N N Y Y Y N N N N N N N 102 1.02 14.4 13.84 Y N Y N N Y Y Y N 8.7 7--9 6500 3.91 26.9 68.9 22.4 32 27.5 2.2 0.5 155.4 46.5 76.96 201.96 220.1 317 5.16 100 15.84 MHA N 9.0 0.6 9.4
29 Elavarasan 3 1--5 M 3 PT Y 0.6 0.6 5 NV N N N N N N Y Y N Y N N N N N N 95 0.95 12.3 13.63 Y N N  N N N Y Y N 7.3 7--9 16500 5.09 24.4 47.9 14.3 30 20.1 3.43 1 31.3 454 6.45 485.6 4.5 915 12 20 10 NNA N
30 Yokesh 2 1--5 M 2 T Y 4 7 4.5 NV Y Y N N N N N Y N Y N N N N N N 78 0.78 11.5 18.90 Y N N  N N Y N N N 10.9 9--11 7400 5.8 33.3 57.3 18.7 33 21.6 2.22 0.9 51.48 263 16.40 313.98 200.5 431 25.2 13 5.5 NNA N
31 maharaj 10 5--10 M 2 T Y 6 0 7 NV Y N N N N N N Y N Y Y N N N N N 127 1.27 30 18.60 Y N N  N Y Y N N N 7.8 7--9 6300 4.44 27.5 62 20.1 32 27.3 5.5 1.6 41.64 415 9.12 456.44 21.1 559 25.2 25 6 NNA N
32 Thrishika 1.5 1--5 F 2 T Y 3 4 5 v Y N N N N N Y Y N N N N N N N N 81 0.81 9 13.72 Y N N  N Y Y N N N 6.7 >=7 9500 4.5 22.3 49.3 14.7 30 22.1 3.12 0.4 26.5 516 4.88 542.9 103 586 7.91 10 0.34 MHA N N N N
33 Suriya varman 1 1--5 M 2 T Y 6 0 7 V N N N Vfever N N N N N N N N N N N N 68 0.68 7.45 16.11 Y N N  N N N Y Y N 9.1 9--11 7300 3.87 27.8 72 23.6 33 16 2.22 0.8 33.75 308 9.89 341.25 199.3 463 13.42 35 1.38 NNA N
34 Divesh 1 1--5 M 2 T Y 1.5 1.5 7 NV N Y N Dysentery N N N N N N N N N N N N 77 0.77 8.65 14.59 Y N N  N N N N N N 7.8 7--9 12600 4.01 26.5 66 19.4 29 17.5 3.16 1 22 269 7.56 291.1 37.8 786 13.06 4 26.27 MHA N 9.4 1.0 11.5
35 Pramila 6 5--10 F 3 T Y 2.5 0 3 V Y N N Vfever N N Y N N N N N N N N N 100 1 16 16.00 Y N N  N N N N N N 10.2 9--11 11800 4.03 31.2 77 25.2 33 11 2 0.4 25.12 248 9.20 273.02 52 425 4.25 37 63.71 NNA N
36 Jayashree 10 5--10 F 3 T Y 6 6 6 NV Y Y Y N N N N N Y Y N N N N N N 131 1.31 27 15.73 Y N N  N N N N N N 10.6 9--11 10500 4.06 32 79 26.2 33 12 3.02 1 83.56 269 23.68 352.86 59.3 343 5.58 28 1.38 NNA N
37 Swetha 9 5--10 F 2 T Y 3.5 0 5 NV N N N N N N N Y Y Y Y N N Y Y N 138 1.38 33.2 17.43 Y N N  N Y N N N N 10.7 9--11 7300 3.89 33.1 85 27.6 32 10.2 2.18 0.4 100.8 242 29.37 343.2 22 629 11.54 6 0.21 NNA N
38 Deenaprasandan 1 1--5 M 2 PT Y 5 7 5 NV N N N
Hypocalce
micseizures N N N N N N N N N N N N 72 0.72 7.5 14.47 Y N N  N N N N N N 8.4 7--9 20000 4.51 28.6 63 18.7 30 12 4.68 0.8 34.79 328 9.60 362.49 115.2 540 20.31 76 320.3 MHA N 9.6 0.6 11.5
39 Praveen 8 5--10 M 3 T Y 6 6 6 NV N N N N N N N N N Y N N N N N N 122 1.22 19.3 12.97 Y N N  N N N N N N 10.6 9--11 11600 4.46 30.8 69.1 23.7 34 12.8 6.51 0.8 49.74 302 14.13 352.04 69.4 941 3.23 12 10 NNA N
40 Sairam 3 1--5 M 2 T Y 6 6 6 V N Y N
bronchopne
umonia N N N Y N Y N N N N N N 90 0.9 10 12.35 Y N N  N Y N N N N 10.3 9--11 8300 3.61 29.1 80.5 28.4 35 13.1 2.72 0.8 102.2 195 34.35 297.62 25 242 12.8 13 10 NNA N
41 Nilson 9 5--10 M 3 PT Y 3 4 5 NV Y N Y N N N N N N N N N N N N N 121 1.21 18.7 12.77 Y N Y N N N N N N 9.6 9--11 7200 4.11 29.1 70.8 23.3 33 16 4.09 0.8 36.53 266 12.08 302.43 45.7 965 3.24 94 32.88 NNA N
42 Jaitheeasri 1.5 1--5 F 2 T Y 3 4 5 NV N N N UTI N N N Y N Y N N N N N N 80 0.8 10 15.63 Y N N  N N Y N N N 5.9 >=7 10500 3.19 18.4 58 18.5 32 11 6.88 0.4 47.76 365 11.57 412.96 11.6 451 9.53 74 10.87 MHA N 8.3 0.3 9.0
43 kamesh 1 1--5 M 2 T Y 6 0 7 NV N N N
Atypicalfeb
rileillness N N N N N N N N N N N N 79 0.79 10.4 16.66 Y N Y N N N Y N N 8.4 7--9 7300 4.5 28 62 18.6 30 18.2 1.13 0.1 17.47 441 3.81 458.07 6.1 296 6.24 19 19.71 MHA N 8.9 0.5 10.2
44 Monish 4 1--5 M 3 T Y 5 7 5.5 V Y N N N N N N N N N N N N N N N 93 0.93 11.5 13.26 Y N N  N N N N N N 10.8 9--11 12200 4.15 31.8 76.6 26.1 34 14.2 3.25 2.2 50.64 343 12.85 393.94 18.2 524 17.55 17 1.44 NNA N
45 Gracy 6 5--10 F 2 T Y 6 6 7 NV Y N N
Bronchiolit
s N N N N N N N N N N N N 100 1 11.7 11.70 Y N N  N N N N N N 9.6 9--11 13800 4.05 30.8 76 23.8 31 11 3.47 0.4 16.78 267 5.91 283.98 113.4 482 14.55 39 11 NHA N
46 Tamilselvan 10 5--10 M 3 T Y 6 12 6 NV Y Y N N N N N N N N N N N N N N 121 1.21 18.6 12.70 Y N N  N N N N N N 8.1 7--9 7900 4.78 26.7 55.8 17 30 18.9 3.45 0.8 46.73 417 10.08 463.42 1.6 ### 8.46 24 0.43 NHA N
47 Naveen 5 1--5 M 2 T Y 5 12 5.5 V Y Y N Walri N N Y Y Y N N N N N N N 108 1.08 16.9 14.63 Y N N  N N N N N N 10.3 9--11 11800 4.38 35.4 80.9 28 35 13 3.25 1.6 33.12 363 8.37 395.72 42 392 12.5 49 11.57 NNA N
48 Nikilesh 3 1--5 M 2 T Y 5 6 5 NV Y Y N N N N N N N Y N N N N N N 94 0.94 13 14.71 Y N Y N N N N N N 8 7--9 4000 4.26 24.1 56.6 18 32 11 1.55 0.7 13.02 430 2.94 443.12 10.1 366 17.14 7 5 MHA N 9.1 0.8 10.1
49 Kalaiselvi 2 1--5 F 2 T Y 9 0 9 NV N N N N N N Y Y N Y N N N N N N 78 0.78 7.2 11.83 Y N N  N Y Y N Y Y 8.4 7--9 11200 4.31 26.6 61.7 19.5 32 18.4 3.05 0.8 14.77 435 3.28 449.77 194 ### 6.35 23 90 MHA P 9.5 1.0 11.2
50 Jayan 2 1--5 M 2 T Y 1 2 5 NV N N N
Atypicalfeb
rileillness N N N N N N N N N N N N 79.5 0.8 9 14.24 Y N N  N N N N N N 10.5 9--11 7300 5.13 31.8 62 20.4 33 17.2 4.59 1 15.49 361 4.12 376.19 50 512 10.42 20 1.84 NNA N
51 Saran 10 5--10 M 2 PT Y 6 10 6 V N N N N N N N N N N N N N N N N 70 0.7 6.87 14.02 Y N N  N N N N N N 9.2 9--11 22700 4.57 32.6 71.4 24.2 34 14.3 6.75 1.5 55.85 423 11.67 478.63 10.1 130 17.34 11 0.31 NNA P
52 Dharun 2 1--5 M 2 PT Y 7 0 7 V Y N N
bronchopne
umonia N N N N N N N N N N N N 82 0.82 8.3 12.34 Y N N  N N N N N N 7.3 7--9 4500 3.2 24.1 75 22.7 30 19.1 14 0.2 14.42 240 5.67 254.12 11.1 575 12.21 80 27.59 NNA N
53 Rukesh 4 1--5 M 2 T Y 7 12 7 NV N Y N N N N N Y N Y N N N N N N 98.8 0.99 14 14.34 Y N Y N N Y N N N 10.1 9--11 12600 4.45 32.3 73 22.6 31 11.2 1.76 0.4 66.27 401 14.18 467.47 15.8 594 12.61 112 0.18 NNA N
54 Yuvaraj 9 5--10 M 2 T Y 6 0 6 NV N N N N N N N N N N N N N N N N 118 1.18 18.1 13.00 Y N N  N N N N N N 9.8 9--11 5900 4.14 31.4 76 26.4 35 12.7 21.3 0.8 36.22 270 11.84 305.92 56 587 8.96 23 14.7 NNA N
55 Anisha 1 1--5 F 2 T Y 5 5.5 5 V Y N N N N N N Y N Y N N N N N N 78 0.78 8.6 14.14 Y N N  N N N N N N 10 9--11 12300 4.26 30.6 71.8 23.4 33 10.8 3.4 0.7 42.93 354 10.83 396.53 8.12 350 15.26 9 5.5 MHA N 10.5 0.2 11.8
56 Saranya 10 5--10 F 4 T Y 6 0 9 NV Y N N Vfever Y N N N N N N N Y N N N 146 1.46 30 14.07 Y N N  N N Y N N N 10.8 9--11 8400 4 31.3 78.2 26.9 34 14 2.91 0.9 96.39 301 24.26 397.39 42 482 15.15 11 5 NNA N
57 Yokeshwari 9 5--10 F 2 T Y 5 5 5 NV Y N N N N N N Y N Y Y Y Y Y Y Y 126 1.26 24 15.12 Y N Y N Y Y N N N 7.8 7--9 4800 2.88 22.7 79 27.3 35 18.9 4.44 0.4 44.81 194 18.75 239.01 25 161 16.5 4 5.3 MHA N 9.1 1.0 9.8
58 Krish sudharsan 6 5--10 M 2 T Y 6 0 6 NV Y N N N N N N Y N Y N N N N N N 107 1.07 14 12.14 Y N N  N N N N N N 9.8 9--11 27200 3.62 29.6 81.9 26.9 33 13.7 2.46 0.8 52.16 251 17.20 303.26 32 738 17.82 31 14.8 NNA N
59 Johnjonathan 5 1--5 M 2 T Y 6 7 6 NV N Y Y N N N Y Y N Y N N N N N N 101 1.01 14.5 14.21 Y N Y N Y N N N Y 10.3 9--11 9300 4.36 33.9 78 23.7 31 12.2 3.07 0.6 62.23 292 17.55 354.49 139 760 6.1 29 12 NNA N
60 Prince Bhavya 5 1--5 F 1 T Y 1 2 6 V N N N N N N N Y N N N N N N N N 90 0.9 24 29.63 Y N N  N N N N N N 10 9--11 5900 4.9 34.2 70 20.4 29 16.8 2.52 0.8 67.08 370 15.36 436.78 35.1 523 4.42 10 5.3 NNA N
61 Kamaleshwaran 1.5 1--5 M 2 T Y 2 3 4 NV N N N
Denguefeve
r N N N N N N Y N N N N N 79 0.79 11 17.63 Y N N  N N N N Y N 10.1 9--11 9700 4.37 33.4 76 23.2 30 11.4 1.25 1.6 34 287 10.61 320.6 12 452 12.32 22 40.7 NNA N
62 Ritesh 1 1--5 M 2 T Y 5 7 5 NV N N N N N N N N N N N N N N N N 73 0.73 8.5 15.95 Y N N  N N Y N Y N 10.5 9--11 10600 4.74 31.7 67 22.7 34 16.1 5.1 0.5 52.76 534 9.00 586.47 86.9 217 12.37 27 2.21 NHA N
63 Yona 5 1--5 F 2 T Y 4 4 6 NV N N N N N N N N Y Y N N N N N N 110 1.1 15 12.40 Y N Y N Y Y N N N 10.5 9--11 6900 4.43 33.4 75.4 24 32 16.2 4.33 0.6 32.99 284 10.39 317.39 29.4 188 18.53 43 12 NNA N
64 Mithra 1 1--5 F 2 T Y 4 4 4 NV N Y N N N N N N N N N N N N N N 67 0.67 7.2 16.04 Y N N  N Y Y N N N 10 9--11 17000 3.8 30.9 81.3 26.6 33 13.5 63.02 1.1 52.7 169 23.74 222 32 234 17.82 11 26.3 NNA N
65 Kabilesh 4 1--5 M 2 T Y 5 5 6 V N Y N N N N N N N N N N N N N N 94 0.94 12 13.58 Y N N  N Y Y N N N 10.4 9--11 9200 4.84 32.1 66.2 21.5 32 17.6 3.26 0.4 37.74 353 9.66 390.54 9.5 455 18.92 21 12 MHA N 10.8 0.5 12.0
66 Mahalakshmi 10 5--10 F 2 T Y 5 6 5 V Y N N
Developme
ntal delay N N Y N Y N N N N N N N 127 1.27 21 13.02 Y N N  N Y Y N N N 6.4 >=7 5100 2.52 21.1 84 25.4 30 13.2 2.82 0.81 65.1 289 18.37 354.4 35.12 396 8.63 33 5.5 NNA N
67 Prabhu 10 5--10 M 2 T Y 3 0 3 NV N Y Y N N N N Y Y N N N N N N N 138 1.38 20 10.50 Y N N  N N N N Y N 9.7 9--11 4200 4.66 33.7 72.4 20.8 29 14.2 1.43 0.9 53.11 235 18.45 287.81 554 352 7.19 67 75.8 NHA N
68 Haroon raship 3 1--5 M 2 T Y 6 6 6 NV Y N N Malaria N N N Y N Y N N N N N N 89 0.89 10.4 13.13 Y N N  N N Y N N N 9.2 9--11 7800 5.73 35 60.1 16 27 12.2 2.92 0.5 24.18 395 5.77 419.18 98 572 7.5 18 12.9 MHA N 9.0 2.0 10.2
69 Hariharan 1 1--5 M 3 T Y 1 3 8 V N N N N N N Y Y N N N N N N N N 78 0.78 8.5 13.97 Y N N  N N N N N N 8.3 7--9 7300 4.25 27.6 65 19.5 30 15.3 1.91 0.5 27.78 405 6.42 432.58 12.95 356 19.5 31 5.8 MHA N 8.9 2.0 9.7
70 Karthik 10 5--10 M 3 T Y 5 7 5 NV N N N N N N N N N N N N N N N N 135 1.35 30 16.46 Y N N  N N N N N N 10.8 9--11 7300 4.54 38.4 84.5 24 28 11.7 3.36 0.8 74.53 246 23.27 320.23 18.2 452 13.15 27 5 NNA N
71 Harish kumar 3 1--5 M 2 T Y 3 3 7 NV Y Y N
simplefebril
eseizures N N N N N N N N N N N N 86.5 0.87 10.5 14.03 Y N Y N N Y N N N 8.5 7--9 15800 4.73 28 61 17.9 29 10.2 2.5 0.89 35.37 453 7.24 488.67 9.1 473 11.66 63 9.6 MHA N N N N
72 Bharathkumar 9 5--10 M 2 T Y 6 6 6 NV Y N N
Appendicec
tomy N N N N Y N N N N N N N 135 1.35 30 16.46 Y N N  N N N N N N 10.3 9--11 6000 4.33 34.2 78.9 23.7 30 12.2 2.87 0.9 69.81 262 21.02 332.11 66.3 253 4.72 55 9.9 NNA N
73 Deepak 10 5--10 M 2 T Y 3 4 6 NV N N N N N N N Y N Y N N N N N N 127 1.27 25.3 15.67 Y N N  N N N N N N 10.7 9--11 13100 4.88 37.8 77.5 22 82 13.4 2.52 0.5 53.92 371 12.69 425.02 15.9 453 983 9 6.6 NHA N
74 Dharshini 8 5--10 F 3 PT Y 5 11 5 NV N N Y Vfever N N N N N N N N N N N N 115 1.15 19 14.37 Y N N  N N Y N N N 10 9--11 6000 4.84 35.4 73.2 20.7 28 13.9 2.24 0.5 70.64 320 18.07 390.94 55.5 711 6.68 21 30.8 NNA N
75 Joaatha leoma 3 1--5 F 2 T Y 4 5 3 NV Y N N N N N N Y N N N N N N N N 85 0.85 8.4 11.63 Y N Y N Y N N N N 9.2 9--11 9800 4.32 32.4 75 21.4 28 14 2.5 1.2 36.62 233 13.56 270.02 1010 724 25.2 50 43.2 NNA N
76 Sandhya 6 5--10 F 2 T Y 6 8 6 NV Y N N N N N N N Y Y Y N N N N N 123 1.23 39.3 25.89 Y N N  N N N N N N 10.3 9--11 1300 5.16 40.8 79 23.9 30 12.2 4 1.1 68.71 341 16.75 410.11 25.1 343 7.72 18 8.4 NNA N
77 Emancy 2 1--5 F 2 T Y 5 10 5.5 NV Y N N N N N Y Y N Y N N N N N N 80.7 0.81 9.6 14.74 Y N N  N Y N N N Y 9.4 9--11 12200 4.39 32.5 73.9 21.4 29 13.4 6.19 0.8 39.35 308 11.34 346.85 25.2 285 11.45 61 20.7 MHA N 10.6 0.8 11.2
78 Bharathkumar 2 1--5 M 2 T Y 6 24 6 NV N N N N N N N Y N Y N N N N N N 79 0.79 8.5 13.62 Y N N  N Y Y N N N 9.8 9--11 12900 4.5 32.2 68.1 20.8 31 17.4 4.16 0.6 33.47 292 10.28 325.67 58 505 12.5 44 90 MHA N 10.2 1.0 11.5
79 Priyanka 10 5--10 F 2 T N 0.5 1 3 NV Y Y N Vfever N N N N Y Y N N N N N N 136 1.36 24 12.98 Y N N  N N N N N N 10.5 9--11 9800 4.04 35 8.7 25.9 30 12.1 1.95 0.7 56.99 337 14.46 393.99 28.2 227 12.5 5 5 NNA N
80 Sai sugeesh 1 1--5 M 2 T Y 6 6 6 NV N Y N N N N N N N N N N N N N N 67 0.67 8.3 18.49 Y N N  N Y N N N N 9 7--9 8300 4.39 28.9 65.7 20.5 31 14.8 6.43 0.5 34.17 390 8.07 423.67 52 422 12.5 22 9.8 MHA N 10.8 0.2 11.6
81 Thrisha 1 1--5 F 2 T Y 5 0 5 NV N Y N N N N N N N N N N N N N N 75 0.75 7 12.44 Y N N  N Y Y N N N 10.7 9--11 10800 4.42 35 79 24.1 31 14.4 2.9 0.6 52.95 221 19.30 274.35 65 425 12.5 25 14 NNA N
82 Litheeswaran 4.5 1--5 M 2 T Y 4 4 4 NV N Y Y N N N Y Y Y N N N N N N N 108 1.08 17.5 15.00 Y N Y N Y Y N N N 10.4 9--11 12800 4.53 34.5 76 23 30 13.9 4.5 0.8 20.14 335 5.67 355.14 45.8 222 12.89 63 18 NNA N
83 B/O Kalavathy 1 1--5 M 2 T Y 3 3 6 NV Y N N N N N N N N N N N N N N N 75 0.75 9.5 16.89 Y N N  N N N N N N 7.7 7--9 9800 3.9 23.5 63.7 19.7 31 12.8 6.03 1.75 31.92 320 9.07 351.95 31.9 293 22 12 2.1 MHA N 8.2 2.0 8.6
84 Bharathy 2 1--5 M 2 T Y 7 8 7 NV Y N N N Y N Y Y N Y N N N N N N 93 0.93 11.4 13.18 Y N Y N N N N N N 10 9--11 10500 4.25 34.2 80.6 23.9 30 13.9 4.26 0.8 68.67 275 19.96 343.97 32.5 572 18.25 30 10.3 NNA N
85 Abishek 1 1--5 M 3 PT Y 6 7 6 V N N N N N N N N N N N N N N N N 67 0.67 6 13.37 Y N N  N N N N N Y 9.3 9--11 6800 4.97 32.4 65 18.7 29 16.5 2.68 0.5 25.97 591 4.21 616.97 7.86 756 20.24 35 22 MHA N 9.8 0.5 11.0
86 Thanigaivel 1.5 1--5 M 2 PT Y 3 3 5 V Y N N N N N Y Y N Y N N N N N N 84.5 0.85 9.6 13.44 Y N N  N Y Y N N N 6.6 >=7 12200 5.94 25.6 43 11.2 26 16.9 6.5 0.3 19.38 482 3.87 500.98 15.1 678 21.18 4 10 MHA N 5.7 1.2 7.2
87 Prashanth 6 5--10 M 3 T Y 3 0 3 V N N N Tb abd Y Y Y Y N N N N N N N N 108 1.08 13.7 11.75 Y N Y N Y Y N Y N 10.1 9--11 4900 4.51 33.6 74 22.3 30 16.9 1.48 0.6 71.28 261 21.45 332.38 36 476 16.75 14 50.5 NHA N
88 Pushpak 5 1--5 M 3 T Y 6 6 12 NV Y N N N N N N N Y N N N N N N N 103 1.03 16 15.08 Y N Y N Y Y N N Y 10.8 9--11 9500 4.16 33.2 79.7 25.9 33 13.6 1.86 1.5 35.4 222 13.73 257.82 131.8 452 21.9 21 24.4 NNA N
89 Deepika 10 5--10 F 2 T Y 1 1 3 NV Y N N N N N N Y N Y N N N N N N 148 1.48 27.5 12.55 Y N N  N N N Y N Y 10.3 9--11 8000 4.32 36.5 84.5 23.8 28 12.4 2.24 1.2 12.83 254 4.81 266.93 1139 772 13.35 12 90 NNA N
90 Sanjay 3 1--5 M 3 T Y 1 2 6 NV N N N
Seizure
disorder N N Y Y N N N N N N N N 106 1.06 16 14.24 Y N N  N N Y N N N 10.2 9--11 7000 4.32 38.5 84.5 28.8 29 10.4 2.16 0.5 56.4 386 12.74 442.6 13.1 375 10.9 8 24 NNA N
91 Vishal 6 5--10 M 3 T Y 4 5.5 4 NV N Y N
bronchopne
umonia N N Y Y Y N N N N N N N 104 1.04 14.8 13.68 Y N N  N N Y N N N 9.8 9--11 11400 4.02 31.9 79 24.4 31 12.4 4.96 0.9 47.6 264 15.27 311.8 37 684 6.33 11 21 NNA N
92 Vimalraj 3 1--5 M 4 PT Y 1 1 8 NV Y Y N
simplefebril
eseizures N N Y Y N Y N N N N N N 81 0.81 8.2 12.50 Y N N  N N Y Y Y N 10.8 9--11 9600 4.52 36.4 80 24.1 30 12 2.97 0.7 24.87 293 7.83 317.67 51.3 492 11.85 22 58.9 NNA N
93 Kamalesh 10 5--10 M 3 T Y 8 12 8 NV N Y Y N N N Y Y N Y N N N N N N 135 1.35 22.5 12.35 Y N Y N Y Y N N N 6.2 >=7 10000 3.77 20.4 56.6 16.2 29 20.7 3.97 1 15.14 412 3.54 427.14 66 452 13.8 18 0.28 MHA N 5.3 1.4 9.3
94 Elavarasan 3 1--5 M 3 PT Y 8 9 8 NV N N N N N N Y N N N N N N N N N 105 1.05 12.3 11.16 Y N N  N N N Y Y N 7.3 7--9 16500 5.09 24.4 47.9 14.3 29 20.1 2.43 0.8 31.3 455 6.44 485.8 4.5 915 12 10 7 MHA N 8.0 2.0 9.1
95 Rithika 2.5 1--5 F 2 T Y 8 8 8 NV N N N N N Y N Y N N N N N N N N 76 0.76 11.3 19.56 Y N N  N N N N Y N 9.2 9--11 14500 4.46 29.7 6.7 19.6 30 12.8 3.19 0.5 22 408 5.12 429.9 65 452 14.2 15 4 MHA N 9.8 1.0 11.5
96 Maana sree 1 1--5 F 2 T Y 6 0 6 NV N N N N N N N N N N N N N N N N 73 0.73 7.6 14.26 Y N Y N Y N N N N 8.7 7--9 18600 4.39 28 64 19.7 31 13.1 2.9 0.6 23.41 440 5.05 463.11 72 522 13.04 12 6.5 MHA N 9.6 1.0 10.5
97 Ranjith 1.5 1--5 M 2 T Y 7 12 7 NV N N N Vfever N N N N N N N N N N N N 85 0.85 9.1 12.60 Y N N  N N N N N N 7.9 7--9 8200 4.52 27.2 65 22.2 28 13.4 4.3 0.6 27 452 5.64 479 10 652 20.2 6 12 MHA N 9.4 2.0 11.5
98 Harini 10 5--10 F 2 T Y 4 4 6 NV Y Y N N N N N N Y Y N N N N N N 132 1.32 25.6 14.69 Y N N  N N N Y Y N 9.8 9--11 8900 4.46 29.2 65.5 21.9 33 16.5 3.26 0.8 15.8 380 3.99 395.5 2.8 743 5.4 21 0.13 MHA N 11.6 0.8 12.0
99 Monika 1 1--5 F 3 T Y 6 6 6 NV Y N N N N N N N N N N N N N N N 94 0.94 8.4 9.51 Y N N  N N N N N N 9.7 9--11 11500 4.2 28.5 67.9 23 34 15.4 3.44 0.7 31.46 412 7.09 443.46 57.8 228 9.29 22 4.02 NNA N
100 Jagatheesh 2 1--5 M 2 T Y 3 3 7 NV Y N N Vfever Y Y N Y N N N N N N N N 91 0.91 14 16.91 Y N N  N N N N N N 10.4 9--11 10000 4.8 34.2 75.4 21.6 29 16 3.2 0.7 56.12 390 12.59 445.62 28.1 695 10.72 2 12 NNA N
101 Mahathi 1.5 1--5 F 2 T Y 6 6 6 NV N N N Vfever N N N N N N N N N N N N 76 0.76 7.8 13.50 Y N N  N Y Y N N N 10.8 9--11 15500 4.69 37.7 80 23.3 29 12 1.87 0.8 48 317 13.16 364.7 33.4 625 11.83 19 9.4 NNA N
102 Sasikumar 2 1--5 M 3 T Y 4 4 4 NV N Y N N N N N N N N N N N N N N 127 1.27 25.3 15.67 Y N N  N Y Y N N N 5 >=7 8600 3.47 16 46 11.6 25 12.2 4.28 1.1 17.13 500 3.32 516.63 2.9 834 6.29 9 5 MHA N 6.7 2.0 7.5
103 Shanthi 10 5--10 F 3 T Y 0 1 5 NV N N N
simplefebril
eseizures Y N N Y Y N N N N N N N 118 1.18 25.5 18.31 Y N N  N Y N N N N 10.1 9--11 8000 3.75 32.9 88.8 26.8 31 11.5 1.46 1.7 110.4 120 47.95 230.34 54.5 505 4.54 23 5 NNA N
104 Karthikrraj 10 5--10 M 2 T Y 6 0 6 NV Y Y N N N N N Y N Y N N N N N N 142 1.42 33.6 16.66 Y N N  N N N N N N 9 7--9 10500 3.76 29.9 80 23.9 30 12.8 3.3 0.4 39.27 243 13.93 281.87 132.8 325 3.47 85 32.3 NNA N
105 Shamini 2 1--5 F 3 T Y 5 6 5 NV Y N N N N N Y Y N Y N N N N N N 78 0.78 9 14.79 Y N N  N Y Y N N Y 8.2 7--9 11100 4.2 27.9 66 19.5 29 12.5 2.5 1.1 20.36 380 5.09 400.06 18.6 485 7.59 15 12.3 NHA N
106 Bhakyalakshmi 8 5--10 F 2 T Y 5 5 5 NV Y N N N N N N Y Y Y N N N N N N 122 1.22 18.6 12.50 Y N N  N Y N N N N 10.8 9--11 9700 4.76 40.6 85 26.1 31 12.8 3.98 0.4 80.74 350 18.74 430.74 28.7 247 4.76 12 6.6 NNA N
107 Swathi 8 5--10 F 2 T Y 5 5 5 NV N N N N N N N Y Y N Y N N N N N 122 1.22 24.5 16.46 Y N N  N N Y N N N 10.5 9--11 6700 4.75 37.9 80 24.2 30 14 3.8 0.8 90.2 218 29.25 308.4 30.3 476 8.9 9 5 NNA N
108 Suryaprakash 8 5--10 M 3 T Y 3 0 3 NV Y Y N N N N N Y N Y N N N N N N 124 1.24 20 13.01 Y N Y N N N N N N 10.4 9--11 4300 4.41 34.1 77 23.7 31 12.6 1.82 0.9 80.45 233 25.63 313.85 55 321 12.4 5 5.3 NNA N
109 Sivasubavishnu 2 1--5 M 3 T Y 5 0 5 NV N N N N N N Y Y N N N N N N N N 80 0.8 9 14.06 Y N N  N N N N N N 9.2 9--11 6900 3.92 29.3 74 23.1 31 11.2 2.67 0.8 28.73 341 7.78 369.43 25.2 267 14.8 12 19.5 NHA N
110 Rabitha 10 5--10 F 3 T Y 4 0 4 NV Y N N N N N N Y N N N N N N N N 131 1.31 33.6 19.58 Y N N  N N Y N N N 10.5 9--11 8300 4.78 35.2 73.6 24.8 34 14.6 3.1 1 57.24 439 11.54 495.91 4.4 274 7.96 12 0.28 NNA N
111 Dhanyasree 1.5 1--5 F 2 T Y 6 18 6 NV N Y N N N N Y N N Y N N N N N N 83 0.83 9.6 13.94 Y N N  N Y Y N N N 10.2 9--11 10400 4.25 32.1 75.5 24 32 17.1 5.2 0.6 45.76 306 13.02 351.36 31.1 431 14.52 5 6 NNA N
112 Vidyut 2 1--5 M 2 T Y 7 12 7 V Y Y Y N N N N N N N N N N N N N 84 0.84 18.2 25.79 Y N N  N N N N N N 9.2 9--11 5800 3.9 28.4 73 23.5 32 11.2 2.95 0.5 32 410 7.24 442 23.1 156 13.79 11 6.77 MHA N 10.6 0.5 11.8
113 Mithun 4 1--5 M 2 T Y 3 3 3 V N Y Y N N N N Y N Y Y N N N N N 103 1.03 15.9 14.99 Y N N  N Y N N N N 6.5 >=7 16400 5.45 24.7 45 12 27 16.2 5.75 1.8 10.1 587 1.69 597.1 2.6 461 12.21 15 1.58 MHA N 7.8 1.0 10.2
114 Samreen fathima 5.5 5--10 F 2 T Y 1 1 12 NV Y Y N N N N N Y N Y N N N N N N 102 1.02 16 15.38 Y N N  N Y Y N N N 9.1 9--11 8300 5.6 29.5 52.7 16.2 31 16.7 2.36 5 74.35 259 22.32 333.11 39.9 670 12.39 11 0.22 MHA N 10.6 0.8 12.1
115 Divakar 6 5--10 M 3 T Y 4 4 6 V N Y Y N N N N Y N Y N N N Y Y N 112 1.12 17.8 14.16 Y N N  N Y N N N N 10 9--11 11100 4.41 30.6 69.4 22.8 33 15.4 3.44 0.8 20.11 382 5.00 402.01 4.5 436 8.15 17 0.43 MHA N 10.4 0.5 11.7
116 Keerthirajan 7 5--10 F 2 T Y 4 6 4 NV Y N Y N N N N Y Y Y N N N N N N 108 1.08 18 15.43 Y N N  N N N Y Y N 10.6 9--11 6500 4.29 34.3 80 24.7 31 12.9 2.33 1 50.21 428 10.50 478.21 8.2 172 28.2 14 18 NNA N
117 Subramani 10 5--10 M 3 T Y 10 0 11 NV N Y N N N N Y Y N Y Y N N N Y N 131 1.31 24.3 14.16 Y N N  N Y Y N N N 4.7 >=7 5800 3.88 18.2 46.8 12 26 26.1 3.5 0.9 19.43 486 3.84 505.66 1.3 295 13.3 41 0.25 MHA N 10.5 1.3 11.9
118 Santhosh 5 1--5 M 2 T Y 6 12 6 V Y Y N N N N N Y N N N N N N N N 110 1.1 18.4 15.17 Y N N  N N N N N N 10 9--11 12800 4.75 30.1 63 18.9 298 18 5.25 0.5 26.17 457 5.41 483.53 19 595 16.75 7 1.78 MHA N 7.4 1.2 8.0
119 Pradeep 3.5 1--5 M 2 T Y 5 6 5.5 NV Y Y N N N N N N N Y N N N N N N 95.5 0.96 11.5 12.61 Y N N  N Y N Y Y N 8.6 7--9 13000 4.42 26.3 59.5 19.4 33 16.6 3.13 1 38.2 384 9.05 422.2 12 482 14.8 12 6 NNA N
120 Narendar 5 1--5 M 2 T Y 6 6 7 V N Y Y Vfever N N N N Y Y N N N N N N 101 1.01 14 13.72 Y N Y N N N Y N Y 10 9--11 5400 3.61 29 80.4 27.4 34 12.2 3.66 1 57.82 272 17.54 329.62 483 380 17.25 55 12 NNA N
121 Sahana 4 1--5 F 2 T Y 5 5 5.5 NV N Y N N N N N N N N N N N N N N 87 0.87 11 14.53 Y N N  N Y N N N N 10.2 9--11 11900 4.59 30.3 76.8 20.2 26 14.6 2.74 0.4 53.92 371 12.69 425.02 71.2 431 10.65 36 8 NHA N
122 Shaheel 5 1--5 M 2 T Y 6 6 6 NV N N N N N N Y Y Y Y N N N N N N 104 1.04 11.2 10.36 Y N N  N N N N N N 10.6 9--11 8100 4.33 34.4 79.3 25.3 32 13.5 3.5 0.6 70.15 262 21.10 332.45 5 187 5.72 10 10.2 NNA N
123 Karthik 7 5--10 M 2 T Y 6 0 6 NV N Y N N N N N Y Y Y N N N N N N 109 1.09 16.3 13.72 Y N Y N N N N Y N 9.5 9--11 8500 4.33 30.5 70.5 22 31 18.5 5.73 1.5 37.46 306 10.90 343.66 62.9 360 12.82 40 12 MHA N 10.6 2.0 11.4
124 Thangaraj 10 5--10 M 3 T Y 1.5 1.5 3 NV Y N N N N N N Y N Y N N N N N N 128 1.28 22 13.43 Y N Y N N N N N N 9.9 9--11 6300 4.36 34.6 79.4 22.8 29 12.4 3.5 0.2 74.53 246 23.27 320.23 230.1 792 14.82 49 5 NNA N
125 Arulraj 2.5 1--5 M 3 T Y 5 24 5 NV N N N N N N N N N N N N N N N N 91 0.91 12.1 14.62 Y N N  N N Y N N N 9.7 9--11 10200 3.99 28.4 71.2 24.2 34 15.6 3.17 1 26.86 432 5.85 458.86 4.85 300 13.64 28 15.8 NNA N
126 Abishek 2.5 1--5 M 3 PT Y 7 12 7 NV Y N N N Y N N Y N Y N N N N N N 83 0.83 10.2 14.81 Y N Y N N Y N N Y 7.4 7--9 20000 4.2 43 68 11.6 17 16.3 3.64 0.7 43.69 418 9.46 461.99 12.2 714 25.2 22 8.7 NNA N
127 Liza mondal 2 1--5 F 2 PT Y 6.5 6.5 7 NV N Y N N N N N N N N N N N N N N 84 0.84 10.2 14.46 Y N N  N Y Y N N N 10 9--11 8700 5.06 32.8 65 19.8 31 16.3 3.43 0.6 71.15 320 18.21 390.65 8.6 852 16.4 25 1.25 NNA N
128 Vishnu 5 1--5 M 2 T Y 6 30 6 NV Y N Y N N N N N N Y N N N N N N 118 1.18 18 12.93 Y N N  N N N N N N 10.1 9--11 8900 4.09 30.9 76 24.6 33 16.2 2.76 1 74.52 245 23.34 319.32 19.6 402 9.1 16 3 NNA N
129 Varunikasri 2.2 1--5 F 2 T Y 6 6 6 NV Y Y Y N N N N N N N N N N N N N 81 0.81 10 15.24 Y N N  N N N N N N 9 7--9 10400 5.03 30.4 16.4 19.7 33 16 3.63 0.4 30.7 492 5.87 522.72 32 ### 11.24 54 1.06 MHA N N N N
130 Hansika 1 1--5 F 2 PT Y 3 0 3 NV N N N N N N Y Y N Y N N N N N N 72 0.72 8 15.43 Y N N  N Y Y N N N 7.9 7--9 7800 4.27 26.8 63 18.5 30 12.8 2.8 0.1 18.3 397 4.40 415.7 13.1 18 4.5 16 22 MHA N 7.9 0.5 7.9
131 Balavignseh 8 5--10 M 2 T Y 3 12 3 NV N Y N N N N N Y N N N N N N N N 102 1.02 18.6 17.88 Y N Y N N N N N N 10.1 9--11 8400 3.81 30.8 80.8 26.6 33 13.3 2.8 0.5 53.86 368 12.76 421.98 178 727 11.18 66 11 NNA N
132 Raagav 2.3 1--5 M 3 T Y 3 3 6 NV N Y Y Walri N N N N N Y N N N N N N 86 0.86 11.5 15.55 Y N N  Y Y N N N N 9.4 9--11 29100 5.19 31.2 60 18.1 30 16.3 4.14 0.3 53.96 411 11.61 464.77 12.6 740 3.8 13 0.6 NNA N
133 Sharon roselin 1.2 1--5 F 2 T Y 6 6 6 NV N Y Y loosestool N N Y Y N Y N N N N N N 80 0.8 9 14.06 Y N N  N Y Y N N N 7.9 7--9 11900 8.3 88.2 66 18.7 28 16.2 4.7 0.5 35.12 483 6.78 518.07 5.9 496 12.2 14 13 MHA N 8.6 1.5 9.2
134 Swetha 10 5--10 F 3 T Y 6 6 6 NV N N N N N N N Y Y Y Y N N N N N 138 1.38 25.8 13.55 Y N Y N N N Y N Y 7.2 7--9 4000 3.79 23.9 63.1 19.1 30 22.2 0.75 1 29.7 490 5.71 519.82 20.2 433 15.82 57 2 MHA N N N N
135 Raakesh 4 1--5 M 3 T Y 6 6 7 NV Y N N
bronchopne
umonia N N Y Y Y Y N N N N N N 92 0.92 14.3 16.90 Y N N  N Y Y N N Y 10.2 9--11 10200 4.22 34.8 82.7 26.4 32 13 2.28 0.6 19.8 206 8.78 225.6 1000 282 14.4 28 14 NNA N
136 Sathya 10 5--10 F 2 T Y 5 0 5 V Y Y N N N N N Y N Y Y N N N N N 116 1.16 19.5 14.49 Y N N  N N Y Y Y N 6 >=7 12200 3.08 16 52.1 13.6 26 25.5 5.29 2.4 20.8 225 8.46 245.92 4.12 178 15.7 24 18 MHA N 6.7 2.0 8.1
137 Samuel 1.3 1--5 M 2 T Y 3 3 8 V N Y N
Breathholdi
ngspell N N N Y N N N N N N N N 74 0.74 10.4 18.99 Y N N  N Y N N N N 7.7 7--9 9600 4.28 26.8 63 18 29 18.2 4.52 0.6 12.82 534 2.35 546.63 4.39 390 12.42 9 6 NNA N
138 Abishek 1.9 1--5 M 2 T Y 3 4 4 NV N Y N N N N Y Y N N N N N N N N 82 0.82 10.2 15.17 Y N Y N N Y N N N 8.6 7--9 11000 4.53 30.3 67 19 28 17.8 4.12 1 27.78 406 6.41 433.38 12.89 482 11.4 31 6 MHA N 9.8 0.5 11.8
139 Mohana 6.3 5--10 F 3 T Y 6 6 6 NV N N N N N N N N N Y Y Y N N N N 108 1.08 14.8 12.69 Y N Y N N Y N Y N 9.9 9--11 15200 4 31.6 79 24.7 31 18.5 2.78 0.5 74.35 253 22.75 326.85 65.5 276 10.39 12 18 NNA N
140 Karthik 2 1--5 M 2 T Y 8 0 9 V N N N N N N N N N N N N N N N N 73 0.73 8.3 15.58 Y N N  N Y Y N N N 9.9 9--11 15000 5.02 34 68 19.7 29 13.5 4.7 0.5 37.46 308 10.84 345.66 19.4 177 12.8 9 5 NHA N
141 Ramya 10 5--10 F 3 T Y 7 7 8 NV N Y Y N N N N Y N Y N N N N N N 143 1.43 34 16.63 Y N N  N N N N N N 9.3 9--11 10200 3.78 31.7 84 24.6 29 17.8 3.76 0.4 50.21 429 10.48 479.21 7.72 172 28.2 15 18 NHA N
142 Amit kumar 4 1--5 M 3 T Y 5 6 5 NV Y N N N N N Y Y Y Y N N N N N N 105 1.05 14.7 13.32 Y N N  N Y Y Y Y Y 8.6 7--9 8700 5.75 32 56 14.9 27 19.2 2.57 0.5 17.35 261 6.23 278.45 172 303 10.2 66 58.2 MHA N 9.5 0.8 10.8
143 Smruti sikta veura 2.5 1--5 F 2 PT Y 6 18 6 NV Y N N N N N Y Y N Y N N N N N N 89 0.89 10.9 13.76 Y N Y N N Y Y Y Y 10.2 9--11 9300 4.46 31.9 71.5 22.9 32 13.7 2.16 0.8 34.63 217 13.76 251.73 180 834 12.2 54 28.4 NNA N
144 Dhanasri 1.2 1--5 F 2 T Y 5 5 8 V N N N N N N N N N N N N N N N N 71 0.71 16 31.74 Y N N  N Y N N N N 10.9 9--11 6300 4.4 34.1 77.6 24.9 32 13.5 2.9 1 63.18 379 14.28 442.44 68.4 330 14.42 11 10 NNA N
145 Vishwa 1 1--5 M 2 T Y 6 8 6 V N N N N N N Y N Y N N N N N N N 70 0.7 8.07 16.47 Y N N  N N N N N Y 8.5 7--9 7800 4.51 26.9 59.6 18.9 32 18.9 4.75 0.7 26.17 457 5.41 483.53 6.45 214 16.75 24 7.2 MHA N 9.5 0.5 11.2
146 Hendric paul 4 1--5 M 2 T Y 4 4 6 NV Y N N N N N N Y N N N N N N N N 105 1.05 13.4 12.15 Y N N  N Y Y N N N 8.8 7--9 8200 3.88 28.7 74 22.8 31 13.8 2.48 0.5 18.26 395 4.42 413.26 14.8 364 14.58 10 5.7 MHA N N N N
147 Abinaya 10 5--10 F 2 T Y 1 2 5 NV Y N N N N N N Y Y Y N N N N N N 132 1.32 22.9 13.14 Y N N  N N N N N Y 10.8 9--11 8600 4.36 36.9 84 24.6 29 11.3 3.39 1 52.76 533 9.01 585.58 130 303 12.37 27 26.4 NNA N
148 Krithika 2 1--5 F 2 T Y 3 18 3 NV N Y Y N N N N N N Y N N N N N N 80 0.8 9.1 14.22 Y N N  N Y Y N N N 7.5 7--9 13600 4.69 26.5 56 15.9 28 12 5.42 2 15.73 426 3.56 442.03 20.6 427 6.8 12 6.26 MHA P 8.2 1.5 9.6
149 Maariselvam 6 5--10 M 4 PT Y 6 12 6 NV N Y N N N N N N Y Y N N N N N N 107 1.07 14.2 12.41 Y N N  N N N N N N 10.6 9--11 14800 4.7 36.3 77 23.3 30 12.3 2.8 0.5 58.21 352 14.19 410.33 22.7 588 17.82 25 8 NNA N
150 John jeslin 1.8 1--5 F 2 T Y 5 6 6 NV N N Y N N N N Y N N N N N N N N 79 0.79 9.5 15.22 Y N N  N Y N Y Y N 8.8 7--9 12800 4.23 29.3 69 20.7 30 18.2 4.25 0.8 39.16 282 12.19 321.28 12.2 516 15.65 8 12 NNA N
129
Annexures
130
ANNEXURE-I
PROFORMA
? Name :                                                         Insurance No -
? Age    :
? Sex     :
? Informant :
? Reliability :
? Address     :
? Socio –economic Details
Mother’s education
Father’s education
Annual Income
Occupation
? Socio –economic Status :
? Housing :
131
? History
Term / preterm
Duration of breast feeding
Timing of introduction of cow’s milk /
formula feeds
Introduction of complementary feeds
Diet
Veg?      Non-Veg?
H/o Intake of red meat,
liver and greens
Worm infestation Yes ?           No?
H/O Pica Yes ?           No?
H/O Pagophagia Yes ?           No?
H/O treatment for any infections in the past Yes ?           No?
H/O of GI bleed Yes ?           No?
Family history of hemolytic anemia Yes ?           No?
? Presenting complaints with duration:
?H/o Irritability Yes ?
No?
?H/o Lethargy Yes ?
No?
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?H/o Poor school performance Yes ?
No?
?H/o Easy fatigability Yes ?
No?
?H/o Breathlessness Yes ?
No?
?H/o Palpitation Yes ?
No?
?H/o Chest pain Yes ?
No?
?H/o Dizziness Yes ?
No?
?H/o Headache Yes ?
No?
? Drug History-
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EXAMINATION
ANTHROPOMETRY                                                     VITAL SIGNS
Height
Weight
BMI
GENERAL EXAMINATION
Pallor Yes ?           No?
Icterus Yes ?           No?
Generalized lymphadenopathy Yes ?           No?
Edema Yes ?           No?
Koilonychia Yes ?           No?
Leuconychia Yes ?           No?
Glossitis Yes ?           No?
Cheilitis Yes ?           No?
SYSTEMIC EXAMINTION
CVS -
RS -
ABDOMEN -
CNS -
Temperature
Heart rate
Respiratory rate
BP mmHg)
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INVESTIGATIONS
Parameters Values Reference range
Hemoglobin
1 to 23 months: 10.5 -14 g/dl
2 to 9 years     : 11.5 - 14.5 g/dl
10 to 17 years  : 12.5 -15 g/dl
WBC count
1 to 23months: 6000 -14000
cells/cu.mm
2 to 9 years    : 4000 –
12000cells/cu.mm
10 to 17 years : 4000 -
10500cells/cu.mm
RBC count
6m to 2 years: 3.7 -5.3 million/cu.mm
2 to 6 years: 4.9 – 5.3 million/cu.mm
6 to 12 years: 4 – 5.2 million/cu.mm
PCV
1 to 23 months: 32 -42 %
2 to 9 years     : 33 -43%
10 to 17 years  : 36 -45%
MCV
1 to 23 months: 72 – 88 fL
2 to 9 years     : 76 – 90 fL
10 to 17 years  : 78 – 95 fL
MCH
1 to 23 months: 24 – 30 pg
2 to 9 years     : 25 – 31 pg
10 to 17 years  : 26 – 32 pg
MCHC 32.0 – 36.0 %
RDW 10.0 – 15.0 %
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Platelet count 154000 – 400000 /cu.mm
Reticulocyte count <1%
Serum Iron 50.00 – 120.00 µg/dL
TIBC 250.00 – 400 µmol/L
Transferrin
saturation
15 - 55%
Serum Transferrin 208 – 400 mg/dl
Serum Ferritin 6.0 – 67.0 ng/mL
Serum B12 140.00 – 700.00 pg/mL
Serum Folic acid 1.8-9.0 ng/mL
ESR 5-15 mm/Hr
HsCRP 0.01-2.80mg/l
? Peripheral smear study  :
? Stool for occult blood    :
DIAGNOSIS:
TREATMENT DETAILS:
FOLLOW U P DETAILS
DATE Hb values Remarks
136
ANNEXURE II
PATIENT CONSENT FORM
Study title: PROFILE AND OUTCOME OF NUTRIONAL ANEMIA IN
CHILDREN ATTENDING THE PEDIATRIC DEPARTMENT OF A TERTIARY
CARE HOSPITAL IN CHENNAI
Study center:   ESI-PGIMSR, K.K.Nagar, Chennai
Participant name: Age:                         Sex:
I.P.No:
            I confirm that I have understood the purpose of procedure for the
above study. I have the opportunity to clarify all my queries and doubts
and they have been answered to my satisfaction. Investigator explained
very well about the procedure and I am made aware of the safety,
advantage and disadvantage of the technique.
            I understand that my participation in the study is purely voluntary
and that I am free to withdraw at any time without giving any reason.
            I have understood that the investigator, regulatory authorities and
the ethics committee will have access to my health records both in respect
to current study and any further research that may be conducted in
relation  to  it,  even  if  I  decide  to  withdraw  from  the  study.  I  have
understood that my identity will not be revealed in anyway and
information released to third parties or published, unless as required
under  the  law.  I  agree  not  to  restrict  the  use  of  any  data  or  results  that
arise from the study.
          Without any compulsion I am willing to give consent for the
participation of my child in this study.
Date:                                Signature / thumb impression of patient
Place:
                                                                                          Patient name:
Signature of the investigator:
Name of the investigator:
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ANNEXURE III
Sample size Calculation
The following were the statistical considerations.
Single Proportion – Absolute Precision
Expected Proportion 0.75
Precision (%) 7
Desired confidence level (1-
alpha) %
95
Required sample size (n) 147
The required sample size for this study was 147 participants. 3
cases were taken as lost to follow up. So, 150 participants were enrolled.
Therefore, total sample size was 150 for this study.
The following were the sample size calculations for the interventional
study.
Single Mean - Paired t-test
Pre-test mean 8
Post-test mean 9
Standard deviation in Pre-test 2.2
Standard deviation in Post-test 2
Effect size 0.47619
Power (1-?)% 90
Alpha Error (%) 5
1 or 2 sided 2
Required sample size 48
2 sided: Null hypothesis: There is no difference between before and
after treatment.
So,  a  total  sample  size  of  50  was  taken  for  follow  up  study
including lost to follow up. The Master software (version 1.0) was used to
calculate sample size.
